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ABC                      Activated B-cell like 
AID                       Activation-induced cytidine deaminase 
ALL                      Acute lymphoblastic leukemia 
API2                     Apoptosis inhibitor 2  
BAFF(-R)             B-cell activating factor (receptor) 
BCL2                    B-cell lymphoma 2 
BCL6                    B-cell lymphoma 6 
BCR                      B-cell receptor 
BL                         Burkittt lymphoma 
BLIMP1                B-lymphocyte induced maturation protein 1 
BLNK                   B cell linker protein 
CD                        Cluster of differentiation  
CDKN2A/B    Cyclin-dependent kinase 4 inhibitor A and B 
CDR3                    Complementarity determining region 3  
CLL                      Chronic lymphocytic leukemia  
c-MYC                  Avian myelocytomatosis virus oncogene cellular homolog 
CNS                      Central nervous system  
CSR                      Class switch recombination 
DC                        Dendritic cell 
DHBCL                Double hit B-cell lymphoma   
DLBCL                 Diffuse large B-cell lymphoma 
EBF                      Early B-cell factor 
EBV                      Epstein-Barr virus  
EDTA                   Ethylenediaminetetraacetic acid 
FL                         Follicular lymphoma 
FOX1                    Forkhead-box protein P1  
GC                        Germinal center 
GCB                      Germinal center B-cell like 
HCV                     Hepatitis C virus 
HHV8                   Human herpes virus 8 
HIV                       Human immunodeficiency virus  
HL                        Hodgkin’s lymphoma 
HSA                      Human serum Albumin  
HTLTV1               Human T-lymphotropic virus 1 
IARC                    International Agency for Research on cancer 
IHC                       Immunohistochemistry 
Ig                          Immunoglobulin  
IgH                        Immunoglobulin heavy chain 
IgV                        Immunoglobulin variable region         
IGVH                    Immunoglobulin variable region of the heavy chain  
IGVL                    Immunoglobulin variable region of the light chain 
IL                          Interleukin 
IPSID                    Immunoproliferative small intestine disease 
IRF4                      Interferon regulatory factor 4 
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IRTA1                  Immunoglobulin superfamily receptor translocation-associated 1 
ITAM                    Immunoreceptor tyrosine-based activation  
LMP2                    Latent membrane protein 2 
LPS                       Lipopolysaccharide 
mAbs                    Monoclonal antibodies 
MALT                  Mucosa associated  lymphoid tissue 
MBL                     Monoclonal b-cell lymphocytosis  
MC                        Mixed cryoglobulinemia 
MCL                     Mantle cell lymphoma 
MSBC                   Monoclonal small B cells  
MUM1                  Multiple myeloma oncogene 1 
MYD88                Myeloid differentiation primary response gene 88 
MZ                        Marginal zone 
MZL                     Marginal zone lymphoma 
NHL                      Non-Hodgkin’s lymphoma 
NF-B                   Nuclear factor kappa B 
NMZL                  Nodal marginal zone lymphoma 
PAX5                    Paired box protein 5 
PCBCL                 Primary cutaneous B-cell lymphoma 
PCR                      Polymerase chain reaction 
PLC2                   Phospholipase C gamma 2  
PMBCL                Primary mediastinal B-cell lymphoma 
RA                        Rheumatoid arthritis  
RAG                     Recombination activating gene 
SHM                     Somatic hypermutation 
SLE                       Systemic lupus erythematosus 
SMZL                   Splenic marginal zone lymphoma 
SS                         Sjögren's syndrome 
ssDNA                  Single strand DNA 
S1P                       Sphingosine-1-phosphate 
TCR                      T-cell receptor 
TD                        T-cell dependent 
T/HLBCL             T-cell/hystocyte-rich B-cell lymphoma 
TI                          T-cell independent 
TLRs                     Toll-like receptors 
TNF                    Tumor necrosis factor alpha 
TRAF                    Tumor necrosis factor alpha receptor associated factor 
VH                        Variable region of the immunoglobulin heavy chain 
WB                       Western blot 
XBP1                    X-box binding protein 1 
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1. General introduction            
A full understanding of B-cell lymphoma, a malignancy of B lymphocytes, is not possible without 
basic knowledge of normal B lymphopoiesis. This introduction will therefore briefly review normal B 
lymphopoiesis and B-cell lymphomagenesis, in particular marginal zone B-cell lymphomagenesis, the 
topic of this doctoral thesis. 
 
1.1 Normal B-cell lymphopoiesis 
            
1.1.1 Immunoglobulin gene assembly and B-cell maturation  
B cells are important to safeguard the human body against invading pathogens. B-cell development 
takes place in distinct anatomic sites. At the same time B cells go through distinct differentiation 
stages that are characterized by the specific structural rearrangement of the B-cell receptor (BCR). The 
BCR is composed of two identical heavy and light chain heterodimers that are covalently linked with 
disulfide bridges. Each of these chains contains a variable region that shapes the immunoglobulin 
domain involved in antigen-binding. Specific antibodies are produced through variable (V), diversity 
(D) and joining (J) segment rearrangement, also called V(D)J recombination as well as somatic 
hyprermutation (SHM) and class switch recombination (CSR). During B-cell ontogeny, the repertoire 
of B cells secreting unique antibodies is generated at two stages; a primary B-cell repertoire is 
generated in the bone marrow, while a secondary B-cell repertoire is formed in peripheral lymphoid 
tissue (Figure 1).  
 
1.1.2 The primary B-cell repertoire 
The primary B-cell repertoire is generated by a random but ordered recombination of 51 variable (V), 
27 diversity (D) and 6 joining (J) segments of the immunoglobulin (Ig) heavy chain gene on 
chromosome 14, and V and J segments of the Ig or Ig light chain on chromosome 2 and 22, 
respectively (MacLennan, 1994). V(D)J rearrangement is mediated by recombination activating gene 
proteins  1 and 2 (RAG1  and RAG2) during the early stages of B-cell development  in the bone 
marrow. These two proteins recognize short recombination signal sequences (RSS) located adjacent to 
V, D and J segments (Gellert, 2002). Successful rearrangement of the immunoglobulin heavy and light 
chain genes leads to synthesis of a complete immunoglobulin IgM molecule. B cells at this stage are 
called immature B cells. While still in the bone marrow, immature B cells develop further into IgM 
and IgD expressing cells called mature naïve or virgin B cells. Precursor B cells  in the bone marrow 
that fail to produce functional antibodies or express potentially harmful autoreactive antibodies are 
eliminated through apoptosis, clonal deletion or receptor editing of the rearranged  or  L chain 
(Rajewsky, 1996). Whereas mature, naïve B cells expressing functional BCRs leave the bone marrow 
and migrate to secondary or peripheral lymphoid organs, i.e. lymph nodes, tonsils, spleen and mucosa-
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associated lymphoid tissues (MALT), where they form B-cell follicles. B-cell follicles are highly 
specialized structures that comprise distinct micro-anatomical compartments such as germinal center 
(GC), also known as the follicle center, and the mantle zone. The mantle zone is composed of the 
lymphocytic corona and the marginal zone in the spleen, extra nodal lymphoid tissue and Peyer’s 
patches. A marginal zone is not usually seen in prepherial lymph nodes (De Wolf-Peeters and Delabie, 
1993).  
 
         
Figure 1. Schematic representation of the B-cell development  
The formation of the primary B-cell repertoire occurs in the bone marrow, whereas the secondary B-cell 
repertoire is generated in the secondary lymphoid organs. Abbreviations: CSR (Class switch recombination) 
SHM (somatic hypermutation), (Reprinted with permission from Sagaert et al., 2007). 
 
 
1.1.3 The secondary B-cell repertoire 
The secondary B-cell repertoire is generated when naïve B cells are recruited into germinal centers 
upon antigen encounter. Mature germinal centers are divided into dark and light zones and different B-
cell subsets are recognized in these zones. A rapidly proliferating subset of B cells known as 
centroblasts occupy the dark zone of the GC, whereas the resting B cells called centrocytes are seen in 
the light zone (MacLennan et al., 1997). In the dark zone of the germinal center, antigen-activated B 
cells clonally expand subsequent to appropriate stimulation by CD4 T cells through CD40- CD40L 
interactions and dendritic cells (DC). In this zone, rapidly proliferating B cells undergo somatic 
hypermutation (SHM), a process in which mutations such as single nucleotide exchange, small 
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deletions or duplications are introduced in the variable region of the immunoglobulin genes. Some of 
these mutations create amino acid substitutions while other mutations can be silent. Somatic mutations 
are scattered along the length of the transcribed immunoglobulin variable region (IgV) gene. Many 
mutations are disadvantageous because they reduce the ability of BCR to bind to antigen or may 
increase auto-reactivity. This leads to apoptosis facilitated by down-regulation BCL2 and other anti-
apoptotic molecules (Kuppers, 2005). In contrary, a minor fraction of the GC B cells may acquire 
mutations that result in increased BCR affinity to antigen. These cells will be positively selected for 
further differentiation and antibody secretion. The combination of V(D)J rearrangement and somatic 
hypermutaion result in potential synthesis of more than 1012 different BCRs. Antigen-stimulated B 
cells typically show somatic mutations that are typically concentrated in the complementarity 
determining regions (CDRs) of the immunoglobulin heavy chain variable (IGVH) and light chain 
variable (IGVL) genes. The IGVH CDR3 is the most diverse region and encodes the antigen-binding 
pocket of the IgV region. Framework regions show lower mutation rates and need to be considered to 
provide a structural framework for the variable domain. 
Antigen-activated B cells in the GC undergo also second immunoglobulin gene recombination event 
known as class-switch recombination (CSR) (Harriman et al., 1993). Through the class switching 
process either  the C or  C exon of the heavy chain constant (CH) gene  coding for  IgM  or IgD 
subclasses, respectively,  is replaced by C,  C or C allowing  the production of IgG, IgA or IgE, 
respectively. In human, nine immunoglobulin heavy chain isotypes are found; IgM, IgD, IgE, IgG1, 
IgG2, IgG3, IgG4, IgA1 and IgA2. Class switching results in a change in effector functions of the 
antibody molecule, but this process leaves the antigen binding specificity of the antibody unchanged. 
B cells expressing high-affinity antibodies for their antigen are positively selected to differentiate to 
plasma cells or long-lived memory cells and exit from the germinal center into peripheral circulation 
via the marginal zone. B cells producing unfavorable antibodies such as poly-reactive or non-
productive antibodies are eliminated or at least reduced from the repertoire by several checkpoints 
during B-cell development in the bone marrow and the secondary lymphoid tissues (Tsuiji et al 2006). 
In spite SHM and CSR events are two separate processes with different molecular signatures, both are 
strictly dependent on a shared pathway initiated by activation-induced cytidine deaminase (AID). 
Distinct catalytic domains of the AID protein seem to be functionally required for either SHM or CSR 
mediation (Muramatsu et al., 2000; Chaudhuri et al., 2007). The germinal center reaction in peripheral 
lymphoid organs is the principal source of somatic hypermutation (reviewed in Klein and Dalla-Favera, 
2008). However, whether somatic hypermutations occur at other microanatomical regions than 
germinal centers is still controversial (Weller et al., 2001; Weller  et al., 2003; Mao et al., 2004; Weller 
et al., 2004; Weill et al., 2009). 
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1.2 B-cell subsets 
B-cell development goes through two major stages that take place in two functional anatomic sites. At 
the first differentiation stage, B-cell precursors differentiate from haematopoietic stem cells into naive 
mature B cells in the bone marrow. At the second stage naive mature B cells differentiate into memory 
or plasma B cells in secondary lymphoid tissue such as lymph nodes, spleen and mucosa associated 
lymphoid tissues. Based  on the rearrangement and mutation status of the Ig genes and expression of  a 
variety of surface markers and intercellular proteins, 5 B-cell subsets have been identified in the bone 
marrow: Pro-B, Pre-B-I, pre-B-II, immature and mature naïve B cells (reviewed by  Perez-Andres et 
al.,  2010). In secondary lymphoid tissue, in addition to the circulating mature naïve B cells, four other 
B-cell populations have been well characterized: GC B cells, memory B cells, MZ B cells and plasma 
cells. Table 1 summarizes the major human B-cell subsets and their characteristic features. 
The B cell commitment to stem cells is determined by the expression of a set of unique regulatory 
proteins including, transcription factor PU.1, early B-cell factor (EBF), Ikaros, paired box protein 5 
(PAX5) and forkhead-box protein P1 (FOXP1) (Matthias and Rolink, 2005; Medina and Singh, 2005). 
These transcription factors induce the synthesis of  RAG-proteins (RAG1 and RAG2) and  terminal-
deoxynucleotidyl-transferase (TdT), which initiate the assembly of D and J segments of the 
immunoglobulin heavy locus (Pelayo et al., 2006). Precursor cells with successfully joined D and J 
segments are known as Pro-B-cells. Pro-B cells express surface markers including CD22, CD34, but 
not CD19 at this stage (Perez-Andres et al., 2010). Upon subsequent rearrangement of one of the 
heavy gene V segments and the D-JH fragment, the precursor cell express the heavy chain VDJ gene, 
leading to maturation of Pro-B-I cells into early  pre-B cells (Pre-B-I cells) that are phenotypically 
characterized as CD10hiCD19+CD22+CD34hiCD38+CD45lo. Pre-B-I cells give then rise to late Pre-B 
cells (Pre-b-II cells). Pre-B-II cells display typical C10+CD19+CD22+CD38+CD45+ phenotype. Pre-B-
II cells express also CD79A (Ig) and CD79B (Ig	). These two proteins, together with the Ig chain 
and the surrogate light chain (Vpreb and 5) form the pre-B cell receptor (pre-BCR). If the pre-BCR is 
able to bind to the BM microenvironment, Pre-B-II cells are positively selected and further 
differentiate into immature B cells. Expression of a complete IgM molecule on the cell surface is the 
hallmark of immature B cells. They further display the CD10loCD19+CD20+CD22+CD38+CD45+ 
immunophenotype (Perez-Andres et al., 2010). These immature B cells lose CD10 and CD38 
expression as they develop into the mature B-cell state (van Lochem et al., 2004). Mature naïve B cells 
are characterized by expression of IgM+, IgD+ and CD27- surface molecules, and they are typically 
CD19+CD20+CD22+CD38- phenotype.    
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 B-cell stage Ig gene status Somatic mutations Ig production Immunophenotype 
Pro-B cell Germ line Pre-B-cell None 
 
CD22, CD34, TdT 
Pre-B-I cell Joined  DJH segments None -Chain  
 
CD19, CD79a, CD10hi, CD22, 
CD34, CD38, CD45lo, TdT 
Pre-B-II cell Rearranged  VDJH None Cyto-Ig-Chain 
 
CD19, CD79a, CD10, CD22, 
CD38, CD45, TdT 
Immature B 
cell 
Rearranged IgH  and 
IgL genes 
None sIgM  CD19, CD79a, CD10lo, CD20, 
CD22, CD38hi ,  CD45, CD27-
Mature naïve B 
cell 
Rearranged IgH and 
IgL genes 
None sIgM and  sIgD CD19, CD79a, CD20, CD23, 
CD44lo, CD45hi, CD10-,  CD27-
GC B cell Rearranged IgH and 
IgL genes 
Mutated Minimal or 
absent Ig 
CD19, CD79a, CD20hi, CD10, 
BCL-6, CD27het, CD38, CD44, 
CD45hi ,  
Marginal Zone 
B cell 
Rearranged IgH and 
IgL genes 
Mutated and 
Unmutated 
sIgMhi and 
sIgDlo  
CD19, CD79a, CD20, CD21, 
CD27, CD1, CD23-
B-1 B cells
 Rearranged IgH and 
IgL genes 
Mutated and 
Unmutated 
IgM and IgD 
CD5+/-, CD19, CD79a, CD20, 
CD21, CD23,   CD27, CD43hi,  
CD69-,  CD70-
 
Memory B cell Rearranged IgH  and 
IgL genes 
Mutated IgG, IgA, IgM 
IgD 
CD19, CD79a, CD20, CD22hi, 
CD27, CD45hi
Plasma cell Rearranged IgH and 
IgL genes 
Mutated IgG > IgA > 
IgD 
CD19, CD38bright, CD138, 
CD27, CD45 
 
Table 1. Classification of B cells according to their differentiation status  

 B-1 B cells can be subdivided into two subgroups based on the differential expression of CD5; CD11b+ CD5+  
B cells are referred to as B-1a B cells, whereas those that do not express CD5 are termed B-1b B cells. 
(References: Sagaert and De Wolf-Peeters, 2003; Perez-Andres et al., 2010; Griffin and Rothstein, 2012)  
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About 60-70 % of human circulating B-cells are IgM+IgD+CD27- with unmutated IGVH genes and 
represent mature naïve B cells (Klein et al., 1998).  The IgM+IgD+CD27- B cells can be divided into a 
large population of CD5- IgM+IgD+ and a relatively small subset of CD5+IgM+IgD+ B cells (Fischer et 
al., 1997). The CD5–negative IgM+IgD+CD27- B-cell population mature into three B-cell 
subpopulations, GC-, MZ - and B-1- B cells. Theses subsets are central players of adaptive and non-
adaptive immunity. GC- and MZ- B cells are so-called conventional B cells or B-2 cells and are 
localized in distinctive anatomical sites; follicular B cells are located in the B cell follicles, while MZ 
B cells are abundant in the splenic MZ. The follicular naïve B cells represent presumed precursors of 
GC B cells that are involved in T cell-dependent (TD) immune response. MZ and B-1 cells participate 
in T cell-independent (TI) immune responses (Lanzavecchia and Sallusto, 2007). MZ and B-1b cells 
express toll-like receptors (TLRs) that identify a variety of microbial TLR ligands such as bacterial 
polysaccharides (Lanzavecchia and Sallusto, 2007).  
About 15% of the peripheral B-cell pool is CD5+IgM+IgD+CD27-. These cells are likely B-1a cells that 
participate primarily in the TI immune response. At least in mice, B-1a B cells are involved in 
autoimmune diseases and a large proportion of cells produce auto-antibodies, so-called natural 
antibodies with polyreactivity (Casali and Notkins, 1989). The main function of B-1a cells is 
presumably to produce polyreactive IgM auto-antibodies that function as a first-line antigen-
independent humoral defense against potentially harmful pathogens. B-cell lymphocytic leukemia (B-
CLL or CLL) likely arises from B-1 cells (Kipps, 1989) 
About 30-40% of the human peripheral blood cells are IgM+IgD+CD27+ memory B cells that are 
distinguished from naïve B cells by the expression of CD27 on the cell surface (Klein et al., 1998). 
The vast majority of these IgM+IgD+CD27+ B cells show a typically low somatic hypermutation 
frequency of IgH genes. Accordingly these cells were presumed to be post-germinal B cells. It was 
initially proposed that human memory B cells were composed of three categories according to their Ig 
isotype, namely switched B cells (mainly IgG+), IgM+IgD- B cells known also as (IgM-only) and a B-
cell subset of IgM+IgD+. The latter two subsets display a similar phenotype to that of the MZ B-cell 
subset (i.e. IgM+IgD+/-CD21+CD23-CD1c+ and mainly CD5-). However, MZ B cells primarily 
participate in the TI immune response, whereas memory IgM and isotype-switched memory B cells 
are produced in germinal centers during the TD immune response (Weller et al., 2004; Tsuiji et al., 
2006).  Upon a re-encounter with the original antigen, IgM+ memory B cells may undergo new rounds 
of the SHM and isotype-switching resulting in a new batch of IgM and IgG memory B-subsets with 
high mutation frequency (Bende et al., 2007; Reynaud et al., 2012). Indeed, in patients with persistent 
infection such as HIV, as high as 60 mutations can be observed in the IGVH genes of the HIV-specific 
memory B cells (Scheid et al., 2009).      
However, the human IgM+IgD+CD27+ B-compartment is likely more complex than originally thought. 
It is now known that there is a substantial fraction of memory B cells that lack of CD27 expression 
(Wirths and Lanzavecchia, 2005). Moreover, several researchers questioned whether CD27 expression 
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is an unambiguous marker for memory B cells (Weller et al., 2004 Weill et al., 2009). IgM+CD27+ B 
cells are not necessarily generated from germinal centers: for instance, CD40-deficient patients, who 
lack functional germinal centers, may acquire SHM during the generation of the preimmune repertoire 
and are exclusively involved in the TI immune response. More recently, Berkawska and co-workers 
identified 6 memory B-cell subsets (Berkawska et al., 2011). Based on proliferation rate, SHM and 
CSR characteristics of the IgH genes as well as immunophenotype, Berkawska and colleagues 
purposed that memory B cells are generated through three different maturation pathways. IgG+CD27- 
and IgM+CD27+ B-cell subsets are derived from primary GC reactions, IgA+ CD27+ and IgG+ CD27+ 
cells are generated during primary or secondary GC reactions secondary to a TD immune response. In 
contrast, IgA+CD27- and IgM+IgD+CD27+ B cells originate mainly from a TI response in a non-GC 
immune reaction. The naïve B cells that leave the bone marrow circulate through the body via blood 
and lymph vessels and enter the secondary lymphoid tissues on the search for foreign antigens. If they 
do no encounter an antigen, they recirculate between the peripheral blood and lymphoid tissue and 
they die within several days. However, upon encounter with antigen, mature naïve B cells are activated 
either in TI or TD response. Only a small number of antigens can directly activate naïve B cells by 
binding to their BCRs and thus may generate a TI response, however, most antigens are TD as they 
require T-cell help (Sagaert et al., 2007). After antigen encounter, the B cells move to the boundary 
area between the B-cell zone and T-cell zone in search for T-cell help. This movement is directed by 
interactions between chemokine ligands CCL19 and CCL21 produced by the stromal cell in the T-cell 
zone and chemokine-receptor 7 (CCR7), which is rapidly upregulated in B cells in response to antigen 
activation (Reif et al., 2002). Once the antigen-activated B cell encounters with its cognate T cell at the 
border of the B- and T-cell zone, it transforms into a B-blast that may take one of the two following 
pathways (Figure 1): (1) In the extrafollicular pathway, most of B-blasts migrate to the extrafollicular 
area of the lymph nodes where they proliferate and differentiate into short-living transient plasma cells 
and later plasma cells, which rapidly secrete low affinity antibodies that serve as the first line defense 
against pathogens. (2) In the follicular pathway, a few B-blasts will migrate into the primary follicle 
and form the GC where they rapidly proliferate, undergo SHM and CSR, and differentiate into 
memory B cells or plasma cells that secret antibody with high affinity. Communication between B cell 
and T cells is mediated by interaction between CD40, constrictively expressed by B cells and its ligand, 
CD40L expressed by activated T-cell as well as different cytokines and their respective receptors. 
These communication signals drive B-cell proliferation and differentiation. Chemokine receptors 
including CXC5, CC7, and CXCR4 and their respective ligands CXCL13, CC19 (also CCL21) and 
CXC12 play a pivotal role in the control of activated B cells migration within the GC 
microenvironments that support their differentiation into plasma cell or GC cells (Gatto and Brink, 
2010) . 
The molecular mechanisms that regulate differentiation of some GC B cells into plasma B cells or into 
memory B cells are not fully elucidated. However, recent experiments have revealed that the 
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differentiation of GC B cells into plasma cells requires the expression of transcription factors including 
B-lymphocyte induced maturation protein 1( BLIMP1), X-box binding protein 1(XBP1) and interferon 
regulatory factor 4 (IRF4) (Shapiro-Shelef et al., 2005; Klein and Dalla-Favera, 2008).  BLIMP1 
represses PAX5 as well as B-cell lymphoma 6 (BCL6) in plasmablasts and plasma cells terminating 
the differentiation program of B cells (Nera and Lassila, 2006). On the other hand, OX40-OX40L 
mediated interactions and high expression of the interleukins IL-2, IL-3, IL-6 and IL-10 seem to play a 
critical role in directing GC B cells to differentiate into memory cells (Liu and Banchereau, 1997).        
 
1.2.1 Marginal zone B cells 
Splenic MZ B cells are recognized primarily on the basis of their anatomical location and 
morphological features. They reside in the secondary lymphoid tissues, especially   in the spleen and in 
Peyer’s patches of the gut, where an abundant influx of antigens occurs. They are characterized by 
abundant clear cytoplasm and pale irregular centrally positioned nucleus (van den Oord et al., 1986; 
Spencer et al., 1998). These cells have been initially hypothesized to be IgM memory B cells, but 
subsequent studies indicate that they represent a distinct B cell subset related to mouse MZ B cells 
(Weill et al., 2009). 
 Most of our current knowledge on MZ B cells is derived from studies performed in rodents, 
particularly in mice (reviewed in Pillai et al., 2005; Weill et al., 2009). Human MZ B cells share many 
surface markers as well as other properties with mouse MZ B cells. Most importantly, as mouse MZ B 
cells, human MZ B cells are typically IgM+IgD+/-CD27+CD21+CD23-CD1c+(mouse cells express the 
CDd1 isoform)  (Spencer et al., 1998; Martin and Kearney, 2001; Weller et al., 2004). The first three 
markers, namely IgM+, IgD+/- and CD27+, are also molecular footprints of IgM memory B cells (not-
isotype-switched memory B cells). In addition to BCR signaling, Notch2 and its ligand Delta1 have a 
critical role in the MZ B cell development both in human and mouse.  Despite that mouse and human 
MZ B cells share common features, it is now known that they also have striking differences regarding 
their anatomical location as well as diversification properties. Mouse MZ B cells express high levels of 
S1P1 and S1P3 lysophospho-lipid receptors that permit the cells to be retained in the MZ, whereas 
their human B cell counterparts lack such an expression and thus recirculate freely between the MZ 
and blood. Mouse MZ B cells are carrying unmutated IgM molecules and are thought to represent a 
distinct naïve B-cell population, separate from mature follicular B cells and B1 cells (Dammers et al., 
2000). Only a small proportion of mouse MZ B cells have mutated IgM genes, and presumably 
represent memory B cells. Contrary to rodents, mutational analyses of the rearranged Ig genes in 
human showed that the human MZ B cells are a heterogenous B-cell population displaying equal 
proportions of mutated and unmutated genes (Dunn-Walters et al., 1995; Tierens et al., 1999; Stein et 
al., 1999; Weller et al., 2008). It was previously proposed, based on the fact that a large fraction of MZ 
B cells are IgM+ IgD+/- CD27+ and harboring mutated Ig genes, that the MZ of human spleen is a 
reservoir for memory B cells. However, new data suggest that Ig genes in IgM+IgD+CD27+ human MZ 
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B cells have an approximately twofold lower somatic hypermutation frequency than isotype-switched 
B cells or so-called true memory B cells (Weill et al., 2009). Additionally, most switched B memory 
cells express mutated Ig genes with highly restricted CDR3 size, while about half of the 
IgM+IgD+CD27+ human B cells (circulating in blood or residing in the spleen) carry Ig genes 
harboring somatic hypermutations and show irregular CDR3 lengths (Weller et al., 2008). These 
distinct features raise the question whether splenic MZ B cells are IgM memory B cells or belong to a 
separate lineage, as it has been recognized in mice.   
MZ B cells are thought to involve both TI as well a TD immune responses.  It has been suggested that 
MZ B cells, as mouse B-1 B cells, are the source of the most natural antibodies that provide a bridge 
between innate and adaptive immune responses (Martin and Kearney, 2001). Their unique anatomical 
location makes MZ B cells well suited to rapidly respond to blood-borne pathogens. Mouse splenic 
MZ IgM+CD27+ B cells have been identified as a part of TI response against blood-borne antigens 
such as polysaccharide determinants from encapsulated bacteria (Tangye and Good, 2007). 
Furthermore, it has been shown that inflammation and/or TLR signals can induce TI proliferation and 
accumulation of somatic hypermutation as well as a basal level expression of AID in mouse immature 
B cells (Han et al., 2007; Ueda et al., 2007).  
In addition to their role in TI antigen response, MZ B cells may also engage in the TD immune 
response because of their ability to respond to protein antigens and function as antigen-presenting cells 
(Kraal and Mebius, 2006; Allman and Pillai, 2008). The TD antigen response usually generates a GC 
reaction leading to antibody-producing plasma cells and memory cells. Alternatively, MZ B cells may 
perhaps be of a B-cell subset that has pre-diversified its BCR outside GCs in a TD immune response. 
Indeed, IgM+IgD+CD27+ B cells with mutated Ig gene are generated in individuals that are unable to 
develop GCs, despite they have somatic hypermutation in their Ig loci (Weller et al., 2001; Weill et al., 
2009). Maturation outside the GC is also indicated by studies showing that MZ B-cells may acquire 
low level SHMs outside the GC (Tierens et al., 1999; Weller et al., 2004). Therefore, a fraction of 
mutated MZ B cells may have never gone through the GC. As a consequence, it has been proposed 
that these cells might develop outside the GCs and thus not represent bone fide memory B cells (Weill 
et al., 2009). However, the one possibility does not necessarily exclude the other, and perhaps MZ B 
cells with mutations arise in various ways.  
 
1.2.2 Monocytoid B cells 
Monocytoid B cells are localized in the peri-sinusoidal area of the lymph node. These cells are 
especially numerous in various lymphadenopathies caused by infection such as toxoplasma, EBV and 
HIV. The ontogeny and function of moncytoid B cells are as yet poorly understood. The view that 
monocyoid B cells might represent the nodal counterpart of splenic MZ B cells has previously been 
proposed (van den Oord et al., 1986; Nizze et al., 1991).  However, the precise relationship between 
these two B-cell subsets is still debated. The immunophenotype of monocyoid B cells is largely 
 18
identical to that of MZ B cells, as both show expression of pan-B-cell markers (CD20, CD79A and 
PAX5) and lack CD5, CD10 CD23 and CD43. Similar to MZ B cells, a substantial fraction of 
monocytoid B cells carry rearranged immunoglobulin genes with a variable number of somatic 
hypermutations (Tierens et al., 1999; Lazzi et al., 2006). Despite these similarities, the negative or low 
CD27 expression in monocytoid B cells, the absence or low expression of BCL2, CD21 and 
expression of immunoglobulin super-family receptor translocation-associated 1(IRTA1) can be used to 
distinguish monocytoid B cells from MZ B cells  (Johrens et al., 2005; Falini et al., 2012). 
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1.3 Lymphoma  
 
1.3.1 Introduction 
Malignant lymphomas are tumors of lymphoid cells and they make up an estimated 3-4% of malignant 
diseases worldwide (Stewart World Cancer Report. Lyon: IARC Press, 2003). Lymphomas are 
traditionally subdivided into to main groups: Hodgkin’s lymphoma (HL) and non-Hodgkin’s 
lymphoma ((NHL) (Swerdlow, IARC Press, Geneva, 2008) constituting 20-30% and 70-80 % of all 
cases, respectively.  
Lymphomas, in particular B-cell lymphomas, have more than doubled in frequency during the last 
decades in the western world, including in Norway as illustrated in figure 2. The reasons for this 
increase are not certain, but at least some of the increase can be attributed to improved diagnosis, 
increasing age, lifestyle changes, a better registration and environmental factors.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Age-adjusted incidence rates for lymphoma (reproduced from the Norwegian Cancer Registry) 
   
According to current taxonomy of the World Health Organization (WHO), NHL consists of a group of 
closely related yet heterogeneous diseases, and can be classified on basis of their distinctive histology 
as well as immunophenotypic, genetic and clinical features (Swerdlow, IARC Press, Geneva, 2008). 
This WHO classification divides NHL into two main groups; B-cell and T/NK-cell neoplasms. 
Approximately 95% of the lymphomas are of B-cell origin, while 5% are T-cell malignancies 
(Kuppers, 2005). About 15 types of B-cell lymphomas are distinguished in the WHO classification. 
Major B-cell lymphoma subtype are Burkitt’s lymphoma (BL), chronic lymphocytic leukemia (CLL or 
B-CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma 
(MCL) and marginal zone lymphoma (MZL) subtypes.  
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1.3.2 B-cell lymphomas and cell of origin 
The WHO classification recognizes distinct B-cell lymphoma types according to the supposed normal 
B-cell subtype and according to morphology, immunophenotype, genetic abnormalities and clinical 
characteristics (Swerdlow, IARC Press, Geneva, 2008). The study of somatic hypermutation in the 
variable heavy (VH) region sequence of the immunoglobulin genes in lymphoma has been of help to 
identify the cellular origin and developmental stage of a given B-cell lymphoma type (Seto, 2004; 
Klein and Dalla-Favera, 2010). As such, B-cell lymphoma without somatic hypermutations are 
recognized as being of pre-germinal center origin, while those with mutations are traditionally 
believed to be of germinal center or post-germinal center origin (figure 3). Acute lymphocytic 
leukemia (ALL) and most MCL cases do not show somatic hypermutations. FL, DLBCL, BL and 
MZL are lymphoma types that show somatic hypermutations and are thus of germinal center or of 
post-germinal center origin. The demonstration of ongoing hypermutations in immunoglobulin 
variable regions suggests a still active hypermutation process and thus a germinal center origin 
whereas fixed somatic hypermutations indicate a post-germinal center origin. A typical example of a 
lymphoma of germinal center origin is FL. Of interest, some lymphoma types such as CLL and some 
MZL subtypes, consist of both mutated and unmutated subtypes and may thus not have a uniform cell 
of origin, according to this scheme.  
Alternatively, some lymphomas with somatic hypermutations may arise from non-GC B cells that 
diversified and acquired somatic mutations in microanatomical sites other than germinal centers as it 
has been reported that somatic hypermutation can be T-independent and may occur in a non-germinal 
center pathway (William et al., 2002; Weller et al., 2004; Scheeren et al., 2008). 
Gene expression profiling of human B-cell lymphoma and normal B cells has shown to be a more 
elegant tool to characterize the cellular origin B-cell NHL and has allowed to identify previously 
unrecognized subsets of B-cell lymphomas. As such, two main subsets of DLBCL have been 
recognized; one originating from activated B cells and one from germinal center B cells (Alizadeh et 
al., 2000; Rosenwald et al., 2002).  
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Figure 3. Human B-cell lymphoma and their normal B-cell counterparts 
The variable region sequence of immunoglobulin genes (Ig) can be used as a marker to identify developmental 
stages of B-cell lymphoma.  ALL and MCL originate from pre-B and naïve B cells respectively and carry 
unmutated IGVH gens. FL and GC-like DLBCL arise from germinal center B cells (the GC stage) and have 
ongoing mutation in the IGVH genes. The activated B- cell subtype of DLBCL carrying IGVH genes with fixed 
mutations is assumed to be of a post-germinal center B-cell origin. Marginal zone lymphoma including MALT 
lymphoma and splenic marginal zone lymphoma (SMZL) are assumed to originate from post-germinal center 
and perhaps B cells that acquired mutations in other micro-anatomical sites outside the germinal center (cases 
with fixed mutations) but also to a lesser extent pre-germinal center (un-mutated cases) B cells. (Adapted and 
modified with permission from Klein and Dalla-Favera, 2010)  
 
1.3.3 Oncogene translocations in B-cell lymphomas 
Approximately 40% of B-cell NHLs show recurrent reciprocal chromosomal translocations that can 
cause transcriptional deregulation of oncogenes or production of chimeric oncogenic proteins 
(Aukema et al., 2011).  The majority of these translocations arise at the germinal center or post 
germinal center stage of the B- cell differentiation as a consequence of an aberrant SHM and CSR 
process. As a consequence, these translocations involve the Ig loci as well as a variety of partner 
proto-oncogenes. The process results in juxtaposition of proto-oncogenes to an immunoglobulin 
regulatory sequence and leads to deregulated expression of the affected oncogene (Kuppers and Dalla-
Favera, 2001). Aberrant translocations can also arise in the bone marrow due to mistakes occurring 
during the Ig-gene rearranging process and result from illegitimate RAG-mediated V(D)J 
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recombination. Classic examples of these translocations include the t(11;14)/ BCL1-IgH translocation 
in MCL,  the t(14;18)/ BCL2-IgH  translocation in FL,  the t(8;14)/ c-MYC-IgH  translocation in BL 
and DLBCL as well as  the t(3;14)/ IgH-BCL6  translocation in DLBCL. Translocations involving 
immunoglobulin loci have also been described in MALT lymphoma and multiple myeloma (Isaacson 
and Du, 2004; Du, 2007). The consequence of oncogene translocations in B-cell lymphoma are diverse 
and can involve enhanced proliferation, inhibition of differentiation and apoptosis (Seto, 2004). For 
example, aberrant expression of BCL2 inhibits apoptosis (Seto, 2004). Constitutive expression of c-
MYC results in a proliferative advantage and engenders cellular immortalization (Hurlin and Dezfouli, 
2004). Constitutive expression of BCL6 inhibits differentiation to plasma or memory B cells but also 
enhances proliferation (Cattoretti et al., 2005). 
While chromosomal translocations involving Ig loci are a recurrent theme in B-cell lymphomas, non-
Ig involving chromosomal translocations are also observed. The t(11;18)(q21;q21) translocation, 
which fuses API2 and MALT1 genes, occurs in a subset of cases of extranodal marginal zone 
lymphoma (MALT lymphoma) (Akagi et al., 1999; Ye et al., 2003). This translocation results in a 
functional API2-MALT1 fusion gene. The API2-MALT1 fusion protein binds to both TRAF2 and 
TRAF6, and thereby enforces activation of NF-B. In addition, API2-MALT1 expression is enhanced 
by NF-B, resulting in a positive feedback loop (Hosokawa et al., 2005). This results in uncontrolled 
NF-B activation. Two other chromosomal translocations detected in MALT lymphoma, albeit less 
frequently, involve immunoglobulin genes, t(1;14) IgH-BCL10 and t(14:18)/IgH-MALT1. Deregulated 
expression of BCL10 and MALT1 through result of these translocations also leads to activation of the 
NF-B pathway (Nakagawa et al., 2006).  
Some oncogene translocations, such as those involving BCL2 or CYCLIN D1, may not be sufficient 
for malignant transformation as these translocations are also detected in healthy individuals with 
increasing age (Seto, 2004; Roulland et al., 2006; Lecluse et al., 2009). Multiple genetic hits and/or 
epigenetic alterations are thus needed to induce lymphoid malignancy. 
Apart from causing oncogene translocations, the SHM process also introduces low level somatic 
mutation in multiple proto-oncogenes genes including c-MYC, BCL6, PIM1, PAX5, Rhoh, and FAS 
(CD95) (Pasqualucci et al., 2001; Nussenzweig and Nussenzweig, 2010). Some of these mutations 
result in amino acid substitutions and also contribute to lymphomagenesis. However, the pathogenic 
role of many of these mutations is not yet fully elucidated as they have also been detected in non-
malignant germinal center B cells (Liu et al., 2008). 
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1.3.4 Infection and lymphomagenesis 
Although the etiology of each of the lymphoma types is not fully known, bacterial and viral infections, 
inherited and acquired immunodeficiency, autoimmune disorders, genetic disposition as well as 
environmental exposure and occupational risk factors have all been implied (Alexander et al., 2007).                             
Infections or chronic inflammation may initiate lymphomagenesis by promoting increased cell 
proliferation and decreased apoptosis and by blocking differentiation. This increases the risk of 
subsequent genetic alterations that allow lymphoid cells to transform into malignant cells.  Known 
infectious agents involved in B-cell lymphomagenesis are bacteria, viruses and likely protozoa. 
Infection-associated lymphomas can be categorized according to the mechanism of lymphoid 
transformation (Suarez et al., 2006; Engels, 2007). A first mechanism is that in which infection of B 
cells leads to the expression of viral oncogenes that directly promote high proliferation, decreased 
apoptosis and that block differentiation. Epstein-Barr virus (EBV), human T lymphotropic virus 1 
(HTLTV1) and human herpes virus 8 (HHV8) are examples of B-cell transforming viruses. A second 
scenario is chronic immune stimulation leading to sustained lymphoid proliferation followed by 
genetic and epigenetic alternations leading to malignancy represents. Helicobacter pylori (H pylori) 
and gastric MALT lymphomagenesis is the best exemplified chronic antigenic stimulation-driven 
lymphoma. A third mechanism of infection-associated transformation is through decreased immune 
surveillance, such as for example induced by human immunodeficiency virus (HIV) infection 
(Carbone, 2003; Engels, 2007). 
 
1.3.5 BCR signaling and lymphomagenesis  
Upon encounter with antigen and upon receiving appropriate co-stimulatory signals, mature B cells 
expressing an antigen-specific BCR become activated and will mature into plasma cells. In addition, 
naïve mature resting B cells rely on constitutive or tonic BCR signaling for survival (Batten et al., 
2000; Kraus et al., 2004; Monroe, 2006). The latter process is less understood than antigen-dependent 
BCR activation. BCR signaling is initiated when a specific antigen binds to the BCR. Subsequent 
signal transduction is mediated by other components in the BCR-complex. The BCR signaling 
complex is a multi-protein structure that is composed of a transmembrane immunoglobulin with the 
Ig and Ig	 heterodimeric signaling subunit, also known as CD79A and CD79B, respectively (Reth, 
1989). Engagement of the BCR by antigen results in BCR aggregation and triggers tyrosine 
phosphorylation of immunoreceptor-based tyrosine activations motifs (ITAMs) of CD79A and CD79B.  
In return, the activated BCR activates the Src family kinases Lyn, Blk, and Fyn as well as the Syk and 
Btk tyrosine kinase (reviewed by Dal Porto et al., 2004). This assembly initiates the formation of a 
‘signalosome’ composed of the BCR, the tyrosine kinases, adaptor proteins such as CD19 and BLNK, 
and signaling enzymes such as phospholipase C g2 (PLC2), phosphoinositide 3-kinase (PI3K), and 
Vav (Dal Porto et al., 2004). The signalosome activates multiple signaling cascades that involve 
kinases, GTPases, and transcription factors. These cascades result in changes in cell metabolism, gene 
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expression and cytoskeletal organization. BCR signaling is complex and may lead to various 
outcomes, including survival, tolerance, apoptosis, proliferation, and differentiation into antibody-
producing cells or memory B cells. The outcome of BCR signaling is determined by the maturation 
state of the cell, the nature of the antigen, the magnitude and duration of BCR signaling, and signals 
from other receptors such as CD40 and BAFF-R. NF-B is one of the major transcription factors 
activated by BCR stimulation. NF-B is a master transcription factor regulating differentiation, cell 
growth and apoptosis. 
 
The BCR is also expressed by the majority of B-cell NHL (Kuppers, 2005). The BCR expressed by 
malignant B cells as for normal B cells is required for cell survival but may also drive proliferation 
(Kraus et al., 2004). That a functional BCR is of importance for malignant B cells is evidenced by the 
observation that translocations involving Ig loci are overwhelmingly located on the non-productively 
rearranged Ig-gene (de Jong et al., 1989). BCR signaling in both the absence and presence of cognate 
antigen is of importance in the early stage of lymphomagenesis (Klein and Pasqualucci et al., 2010). In 
B-cell lymphoma, BCR signaling can act through at least two major molecular mechanisms leading to 
NF-B activation. The first mechanism involves constitutive activation of NF-B signaling through 
mutations of BCR signaling components. Activating mutations in genes such as CD79A, CD79B and 
CARD11, down stream of the BCR receptor, lead to constitutional NF-kB activation. Such mutations 
are present in a substantial fraction of DLBCL but are less frequent or rare in other B-cell lymphomas 
(Lenz and Staudt, 2010; Staudt, 2010). A second mechanism involves stimulation of the BCR by 
antigen and is seen in clinically indolent B-cell malignancies. In CLL and MALT lymphoma foreign 
and/or auto-antigen activates the BCR which together with co-stimulatory signals, leads to NF-B 
activation.  
 
Some lymphoma types of B-cell origin do not express the BCR or express the receptor only at low 
levels (Kuppers, 2005). Typically, classic Hodgkin lymphoma has lost BCR expression due to the 
introduction of a stop codon or frame shift in the Ig variable-region genes. The latter has also been 
shown in post-transplant lymphoma (Capello et al., 2003). About 40% of cHL and the majority of 
post-transplant lymphoma are infected by EBV and express the EBV encoded latent membrane protein 
2(LMP2). In those lymphoproliferative diseases LMP2 likely replaces the BCR-mediated signaling 
necessary for survival (Kuppers, 2005).  
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1.4 Marginal zone lymphoma 
Marginal zone lymphoma (MZL) comprises distinct lymphoma types, believed to originate from 
marginal zone B cells (Isaacson and Jones, 1983). Depending mainly on the organ in which lymphoma 
arises, the current WHO lymphoma classification recognizes three distinct types of marginal zone 
lymphomas: nodal marginal zone lymphoma (NMZL) , extranodal marginal B cell zone lymphoma  of 
MALT type known as MALT lymphoma  and splenic marginal zone lymphoma (SMZL) arising in 
lymphoma nodes, mucosal sites and the spleen, respectively (Swerdlow, IARC Press, Geneva, 2008). 
MZL represents about 8-10% of all lymphoma, and thus MZL is the third most frequent lymphoma 
type after DLBCL and FL. MZL shares some common immunophenotypic features, but the clinical 
course and molecular characteristics are different for each of the types. 
 
1.4.1 MALT lymphoma 
Extranodal marginal lymphoma of mucosa associated lymphoid tissue (MALT lymphoma) is an 
extranodal lymphoma comprised of small B cells including centrocyte-like cells, which are resembling 
small lymphocytes or so-called monocytoid B cells (Isaacson, 2005). MALT lymphoma is the most 
common MZL. It is a clinically indolent disease and presents at a median age of 60 years (Swerdlow, 
IARC Press, Geneva, 2008). MALT lymphoma preferentially arises in the stomach and small intestine, 
but can occur in almost all mucosal tissues such as lacrimal glands, the thyroid, the salivary glands, 
breast tissue and bronchi. It also occurs in the skin. Interestingly, these organs are under normal 
circumstances devoid of organized lymphoid tissue (Morse et al., 2001). MALT lymphoma is 
therefore thought to arise from acquired lymphoid tissue, such as seen with chronic infection or 
inflammatory disorders. Several infectious agents and inflammatory disorders have been associated 
with MALT lymphomas, among which the association between gastric MALT lymphoma and 
Helicobacter pylori (H pylori) infection is the best characterized.  
MALT lymphoma shares immunophenotypic features with normal marginal zone B cells:  CD20+, 
CD21+, CD35+, IgM+ IgD+/- (Spencer et al., 1985; Swerdlow, IARC Press, Geneva, 2008). MALT 
lymphoma does not typically express CD5, CD10 and BCL6. 
 
1.4.2 Gastric MALT lymphoma and Helicobacter pylori: a model for chronic infection-driven B-
cell lymphomagenesis 
Chronic infection with H pylori, a Gram-negative bacterium, has been closely associated with gastric 
B lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma (Wotherspoon et al., 1991; 
Isaacson, 1995; Isaacson and Du, 2004). Several lines of epidemiological, clinical and molecular 
evidence are linking gastric lymphoma to H pylori infection. First, the incidence of primary gastric 
lymphoma is highest in geographical areas where H pylori infection is endemic (Doglioni et al., 1992). 
Second, H pylori presence has been shown in gastric biopsy samples of the majority of the gastric 
lymphoma patients (Wotherspoon et al., 1991). Third, at the early stages of gastric lymphoma, 
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eradication of H pylori infection by antibiotic treatment leads to complete regression of the disease in 
approximately 75-80% of the patients with this lymphoma (Wotherspoon et al., 1993; Bayerdorffer et 
al., 1995; Roggero et al., 1995). In addition, reinfection with the same strain of H pylori re-induces the 
growth of the lymphoma (Chang and Parsonnet, 2010). Pooled data analysis from 34 studies of more 
than 1270 patients with gastric MALT lymphoma showed that antibiotic treatment achieved 
eradication of infection in 98.3% of cases and that 77.8% of the H pylori-cured patients achieved 
lymphoma remission (Zullo et al., 2009). Fourth, nucleotide sequence analysis of the IgV genes from 
patients with gastric lymphoma supports the concept of the antigen-driven lymphomagenesis. The 
IGVH and IGVL genes of gastric MALT lymphoma are heavily mutated, suggesting antigen exposure 
(Du et al., 1996). However, H pylori infection may by itself not be sufficient to cause lymphoma. At 
least three stages in H pylori–driven lymphomagenesis are recognized (Figure 4); the initiation phase 
or chronic antigenic stimulation stage, the progression phase or immortalization stage and the 
transformation phase or advanced stage. 
In its early stage, gastric MALT lymphoma is a low-grade and antigen-dependent neoplasia. At this 
stage, lymphoma B cells receive signals through their B-cell receptor leading to activation of the NF-
B signaling pathway that promotes increased survival and reduced apoptosis. Of interest, antibodies 
derived from gastric MALT lymphoma are not specific for H pylori antigens but bind to a variety of 
foreign as well as auto-antigens, thus showing polyreactive features (Craig et al., 2010). Reactivity 
with auto-antigens and well as Helicobacter antigens together with CD40-CD40 ligand independent 
help by T cells allows proliferation of B cells. The latter ultimately give rise to lymphoma through 
chronic stimulation (Enno et al., 1998; Bende et al., 2005; Mueller et al., 2005). In this early stage, 
gastric MALT lymphoma can be cured with antibiotic therapy in 75-80% of the cases (Wotherspoon et 
al., 1993).  
With disease progression, additional oncogenic events occur, such as chromosomal translocations, 
inactivation of tumor repressor genes by mutations or hypermethylation leading to enhanced cell 
proliferation. At this stage, the disease becomes independent of antigenic stimulation (Farinha and  
Gascoyne, 2005). Among these changes include hypermethylation of cyclin-dependent kinase 4 
inhibitors including p15 and p16, also termed B and A, CDKN2B and CDKN2A, respectively, 
inactivate cell-cycle regulating genes, leading to a B-cell clonal expansion (Martinez-Delgado et al., 
1997) (figure 4A and 4B). In addition, about 20-25% of gastric MALT lymphoma shows t(11;18), 
fusing API2 to MALT 1 genes or t(3;14) and t(14;18) fusing BCL10 and MALT1 genes to the heavy 
chain of the  immunoglobulin locus,  respectively (Isaacson and Du, 2004). These changes bypass the 
requirement of the BCR stimulation for growth. 
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Figure 4. Infection-associated indirect lymphoid transformation 
 Bacterial antigens or autoantigen(s) could indirectly promote B cell proliferation and formation of neoplasia 
through an uncontrolled, chronic stimulation that may favour the occurrence of still poorly defined secondary 
genetic and epigenetic changes (reprinted with permission from Suarez et al., 2006).  
 
 
1.4.3 Ocular adnexal lymphoma and Chlamydia psittaci  
Ferreri and his colleagues (Ferreri et al., 2004, 2005, 2006A) have proposed an association between 
Chlamydia psittaci (C psittaci) infection and ocular adnexal lymphoma, a MALT lymphoma affecting 
conjunctiva, orbit, eyelid, or lacrimal gland. Subsequent studies have demonstrated that this 
association is dependent on geographical region (Mulder et al., 2006; Chanudet et al., 2006; Du et al., 
2007). Also, C psittaci was shown in lymphoma tissue by PCR (Ferreri et al., 2004). C psittaci DNA 
was also detected in peripheral blood mononuclear cells of patients with lymphoma, but not in healthy 
individuals (Chang et al., 2010). Complete or partial response to antibiotic therapy has also been 
described (Ferreri et al., 2005). Of interest, one-third of C psittaci -negative patients with ocular 
adnexal lymphoma have also shown tumor regression after treatment with antibiotics (Ferreri et al., 
2006B). The latter indicates that perhaps other microbial agents are also involved in the pathogenesis 
of the lymphoma. 
 It is assumed that the role of C psittaci in lymphomagenesis is quite similar to that of H pylori in 
gastric lymphoma. Very recently, Dagklis et al. provided new molecular data supporting relationship 
between IGVH gene repertoire and C psittaci infection in ocular adnexal lymphoma (Dagklis et al., 
2012). Interestingly, approximately 10% of IGVH genes expressed by ocular adnexal lymphomas have 
auto-reactive properties, indicating an origin of the lymphoma from auto-antigen reactive B cells, at 
least in a proportion of cases (Dagklis et al., 2012). 
 
 28
1.4.4 Immunoproliferative small intestine disease and Campylobacter jejuni  
Immunoproliferative small intestine disease (IPSID), also known as alpha heavy chain disease (HC) 
disease or Mediterranean lymphoma, is a rare form of MALT lymphoma. Excessive production and 
secretion of truncated immunoglobulin alpha heavy chain fragments lacking immunoglobulin light 
chain is typical for this lymphoma (Martin and Aldoori, 1994). Of interest, Campylobacter jejuni (C 
jejuni) infection is often associated with this lymphoma. Eradication of the infection by antibiotic 
treatment is strongly suggestive of a causative association between Campylobacter Jejuni infection 
and lymphoma development (Parsonnet and Isaacson, 2004). Up to 40% of lymphomas have shown 
complete regression with antibiotic treatment (Al-Saleem et al., 2005). Lecuit and colleagues provided 
further evidence, based on molecular approaches, supporting a link between immunoproliferative 
small intestinal disease and C. jejuni infection (Lecuit et al., 2004). The pathogenesis of IPSID shows 
many similarities with this of gastric MALT lymphoma (Figure 5) (Parsonnet and Isaacson, 2004). 
 
 
 
Figure 5. The similarities and differences between the pathogenesis of gastric MALT lymphoma (left panel) and 
immunoproliferative small intestine disease (right panel). In both lymphomas, the bacterial infection releases 
auto-antigens and stimulates T cells to produce cytokines, contributing to the proliferation of lymphoid B cells 
(reprinted with permission from Parsonnet and Isaacson, 2004).   
 
 
1.4.5 Primary cutaneous B-cell lymphoma and Borrelia burgdorferi  
MALT lymphoma of the skin has been associated with Borrelia burgdorferi infection in two 
independent studies (Goodlad et al., 2000; Ferreri et al., 2004). Antibiotic treatment with penicillin has 
been an effective as treatment for these lymphomas (Roggero et al., 1995; Kutting et al., 1997). 
However, a significant association between the infection and cutaneous MALT lymphoma has not 
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been found in the USA and Asia (Wood et al., 2001; Li et al., 2003). Therefore, the pathogenesis of 
primary cutaneous B-cell lymphoma is not yet clearly understood. The molecular genetics of 
cutaneous MALT lymphoma differs from that of the other MALT lymphomas (Streubel et al., 2004; 
Schreuder et al., 2005). For instance, the immunoglobulin proteins produced by cutaneous MALT 
lymphoma lacks rheumatoid factor reactivity. In addition, NF-B signaling is probably activated 
through toll-like receptor 2 rather than through the BCR or BAFF as in gastric MALT lymphoma 
(Cho-Vega et al., 2006).  
 
1.4.6 MALT lymphoma and Autoimmunity  
Systemic autoimmune diseases are characterized by immune dysregulation and self-reactive reactivity 
resulting in damage to cells and tissue. In Western countries, roughly 5% of the population are 
suffering of some type of autoimmune disorder. Autoimmune disorders have been recognized as risk 
factors for the development of NHLs. An increased lymphoma incidence has been noted in rheumatoid 
arthritis (RA) (Thomas et al., 2000; Askling et al., 2005; Smedby et al., 2006), Sjögren's syndrome 
(SS) (Theander et al., 2006), systemic lupus erythematosus (SLE) (Mellemkjaer et al., 2008; Smedby 
2008), celiac disease (Askling et al 2002; Catassi et al., 2002; West et al., 2004), dermatitis 
herpeteformis (Sigurgeirsson et al., 1994; Askling et al., 2002) and chronic thyroiditis (Askling et al., 
2005; Mellemkjaer et al., 2008). Interestingly, autoimmune disorders may also develop secondary to 
hematologic malignancies (Ehrenfeld et al., 2001).  
The nucleotide and amino acid sequence analysis of the IGVH repertoire in a comprehensive panel of 
B-NHLs has shown that more than 40% of salivary gland lymphomas in Sjögren's syndrome expressed 
BCRs with strong CDR3 homology to that of rheumatoid factor (Bende et al., 2005). Furthermore both 
VH1-69 and VH3-21 gene segments that have been shown to be preferentially used by MALT 
lymphoma, HCV-associated lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, 
respectively, are also used to produce rheumatoid factors in RA (Baecklund et al., 2006). Equally of 
interest, the synovial tissue of the RA patients contains oligoclonal B-cell proliferations with 
properties of antigen-driven selection (Kim and Berek, 2000). Perhaps these chronically stimulated 
auto-reactive B cells are precursor cells for B-cell lymphomas associated with auto-immune disease. 
 
1.4.7 Splenic marginal zone lymphoma   
 Splenic marginal zone lymphoma (SMZL) is a relatively rare disease comprising 1-2 % of NHL and 
roughly 20% of MZL. It is mostly, but not always, a clinically indolent lymphoma (Swerdlow, IARC 
Press, Geneva, 2008). Most patients with SMZL are over 60 years. There is an equal incidence of 
SMZL in men and women (Matutes et al., 2008). The lymphoma originates in the spleen and spreads 
to the bone marrow in most cases.  Variable numbers of lymphoma cells are also detected in the 
peripheral blood.    
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SMZL is assumed to arise from the splenic marginal zone B cells and have a concordant CD20+, 
CD19+, FMC7+, CD43+/-, IgMhi, IgDlo, CD27+ CD5-/+ immunophenotype (Matutes et al., 2008). 
Skewed VH gene usage is pronounced in SMZL, with about 30% of cases using the VH1-2 genes. 
Also CDR3 regions are very similar in the latter cases (Bikos et al., 2012). This may indicate antigen-
stimulation as part of the SMZL lymphomagenesis (Tierens et al., 2003; Arcaini et al., 2009a). Other 
SMZL are associated with Hepatitis virus (HCV) and also malaria infection has been associated with 
SMZL in geographic areas where these infections are endemic (Bates et al., 1997, Suarez, et al., 2007). 
The largest series of cytogenetic analysis of 330 patients with SMZL showed that 72% of SMZL cases 
exhibit chromosomal aberrations, of which 53% are complex genetic changes (Salido et al., 2010). 
None of these cytogenetic abnormalities are considered typical of SMZL, with the exception of the 
7q32 deletion occurring in 39% of SMZL (Salido et al., 2010). Contrary to MALT lymphoma, 
chromosomal translocations involving the immunoglobulin loci are rarely found in SMZL. 
  
1.4.8 Hepatitis C Virus and splenic marginal zone lymphoma  
HCV is a single strand RNA virus that infects approximately 170 million people worldwide and is one 
of the major causes of liver disease (Mele et al., 2003).  HCV-infection has also been associated with 
mixed cryoglobulinemia (MC) as well as with the development of NHL. This association was first 
described by Ferri and his colleges (Ferri et al., 1994). The finding was later supported by a large 
number of studies including a meta-analysis (Dal and Franceschi, 2006). Of interest, HCV infection is 
associated with specific NHL types including marginal zone lymphoma, chronic lymphocytic 
leukaemia and diffuse large B-cell lymphoma (Viswanatha and Dogan, 2007; Arcaini and Bruno, 
2010). An oncogenic role of HCV in NHL was strengthened by clinical studies showing complete or 
partial lymphoma remission following anti-viral treatment (Hermine et al., 2002; Vallisa et al., 2005). 
Further evidence directly linking HCV virus infection to NHL came from mutational analysis of the 
immunoglobulin variable genes showing the preferential usage of the VH1-69 gene with similar 
CDR3s and preferential usage of the immunoglobulin light chain V4–34 (also known as 325) gene 
in the majority of the HCV-positive marginal zone lymphoma (Marasca et al., 2001).  The VH1-69 
antibodies are typically polyreactive (Ivanovski et al., 1998). It has been proposed that HCV stimulates 
B cells through either interaction between CD81, present on the B-cell surface, and HCV-E2 
glycoprotein, the major envelope protein of HCV (Rosa et al., 2005). Alternatively, HCV may activate 
B cells through interaction between the BCR and HCV-E2 or other HCV antigens. CD81 is a 
multimeric protein known to associate with the CD19 and CD21 complex on the cell surface which 
when activated, stimulates proliferation (Weng and Lau, 2005). It has been also reported that 
antibodies produced by HCV-associated lymphoma B cells react with the viral E2-protein in a manner 
identical to bone fide human anti-E2 antibody, implicating that the B activation is generated by the 
dual binding of the viral E2-protein to a cognate BCR as well to the CD81 molecule (Zignego et al., 
2012). As proposed for other marginal zone lymphoma types, proliferating polyclonal B cells are 
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prone to gain subsequent genetic alterations resulting in growth advantage and ultimately lymphoid 
neoplasia.   
 
1.4.9 Malaria and splenic marginal zone lymphoma 
More than 250 million people worldwide suffer from malaria and nearly 1 million deaths are attributed 
to malaria each year (World Health Organization 2010). Hyperreactive malarial splenomegaly, 
previously known tropical splenomegaly syndrome is a disease of malaria-endemic regions of Africa 
(Fakunle et al., 1978). The syndrome is characterized by massive enlargement of the spleen, fever, 
weight loss, B lymphocytosis and cryoglobulinemia. Evolution of hyperreactive malarial 
splenomegaly to splenic marginal zone lymphoma has been described, thereby strengthening the 
possible role of infectious agents in the SMZL development, but its detailed pathogenesis is as yet 
unknown (Jimmy et la., 1996; Bates et al., 1997; Dascalescu et al., 2004).   
 
1.4.10 Nodal marginal zone lymphoma 
Nodal marginal zone lymphoma (NMZL), also called monocytoid B-cell lymphoma, is a primary 
nodal  B-cell neoplasm  that morphologically resembles SMZL and extra nodal MZL, but without  
evidence of splenic or extra nodal involvement, and represents < 2% of all lymphoid neoplasms 
(Campo et al., 2011). Most cases occur in individuals with a median age of 60-65 years. There is an 
equal incidence in men and women. A subtype of NMZL occurs in the pediatric age group, which has 
distinctive clinical and morphological features, and predominantly occurs in males with a ratio of 20:1.   
Typically, this lymphoma consists of B cells that resemble monocytoid B cells and can be admixed 
with scattered transformed cells. Most nodal NMZL cells express pan-B-cell markers, CD20, CD79A 
and PAX5, with coexpression of CD43 in 50% of the cases.  Typically, these cells lack expression of 
CD5, CD23, CD10, BCL6 and cyclin D1, whereas BCL2 expression is positive in most cases (Campo 
et al., 2011; Arcaini et al., 2009b). Additionally, a recent study showed that IRTA1 is selectively 
expressed in NMZL and extra nodal MZL but not SMZL, thereby can be used as a valuable diagnostic 
marker to distinguish NMZL from SMZL (Falini et al., 2012). Some epidemiological studies have 
reported an association between NMZL and HCV infection (Arcaini et al., 2003; Arcaini et al., 2004). 
Also, the majority of NMZL patients show somatic hypermutation of rearranged immunoglobulin 
genes and preferential usage of VH4-34, suggesting that antigenic stimulation is involved in the 
lymphomagenesis (Traverse-Glehen et al., 2005). The most frequent cytogenetic aberration in NMZL 
is trisomy 3 that occurs in 24% of cases (Rinaldi et al., 2011). However, characteristic translocations 
or chromosome imbalances have not been described in NMZL. 
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2. Aim of the study 
The overall aim of our studies was to further characterize marginal zone-like B cells and lymphomas 
believed to derive from marginal zone B cells. The following questions were addressed. 
1) Do monocytoid B cells acquire somatic mutations outside the context of the germinal center? 
2) Is there evidence for antigen stimulation in lymphomagenesis of splenic marginal zone 
lymphoma?  
3) Can oncogenic mutations be found in genes that regulate NF-B activation in marginal zone 
lymphoma? 
4) Does diffuse large B-cell lymphoma arise from precursor marginal zone-like B cells? 
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3. Methodological   considerations 
3.1 Patient samples and human cell lines 
Tissue, bone marrow and blood samples used in this thesis were retrieved from the archive of the 
department of pathology, the Norwegian Radium Hospital, Oslo University Hospital. The use of 
patient materials was approved by the Oslo University Hospital institutional review board and the 
regional ethics committee.  
In article I, lymph nodes from 10 patients diagnosed with monocytoid B-cell hyperplasia and of whom 
freshly-frozen samples were available were studied. Two lymph nodes from these ten cases were 
selected for microdissection of monocyoid B cells for further analysis. For control studies, peripheral 
blood leukocytes from a healthy donor were obtained.  
In article II, freshly-frozen biopsies from 10 cases of SMZL were selected to produce the antibodies 
expressed by the lymphoma B cells. In addition, the following cell lines were also used in the study in 
this article: HEK293 (ATCC), Jurkat (ATCC), OVCAR-8 (a kind gift of professor Reuven Reich, 
Hebrew University, Jerusalem, Israel), MIA PaCa-2 (ATCC), PANC-1 (ATCC), MIN6 (DMSZ), 
HEP-G2 (DMSZ),  HELA (DMSZ), NALM-6 (DMSZ), KARPAS-422 (DMSZ), SU-DHL-6 (DMSZ) 
and  Daudi (ATCC). 
In article III, the same cases of SMZL studied in articles II as well as 13 control cases of marginal 
zone lymphoma, including 7 nodal, 6 extranodal MALT-type cases, were used to detect potentially 
oncogenic mutations in the NF-B signaling pathway.  
In article IV, diagnostic biopsies, bone marrow aspirates and/or blood samples from 165 consecutive 
patients with a primary diagnosis of DLBCL without histological evidence of concurrent no-
Hodgkin’s lymphomas were examined by routine microscopy of trephines and smear, 
immunohistochemistry and flow cytometry. Paired sample materials comprising diagnostic lymphoma 
biopsies as well as bone marrow of 10 of these 165 cases were available for the analysis of rearranged 
immunoglobulin heavy chain genes.  
 
3.2 DNA and RNA extraction and nucleic acid sequencing 
Genomic DNA and total RNA were extracted from paraffin-embedded materials, frozen tissue, blood 
and bone marrow samples by  either TRIzol® Reagent kit (Life Technologies) or Biorobot® EZI DNA  
reagents and extractor or genomic DNA kit and RNeasy kit protocols (Qiagen, Hilden, Germany) 
according to the manufacturer’s recommendations. The DNA and RNA concentration was measured 
with NanoDrop ND-1000 spectrophotometer (Witeg a.g., Littau Switzerland). The purified DNA and 
mRNA were amplified with the desired primer sets (one step reverse-transcriptase-polymerase-chain 
reaction, RT-PCT was performed when RNA is used). The PCR products were either directly 
sequenced or cloned into the respective expression vector and then sequenced from both orientations 
with the use of ABI Prism Dye Terminator Cycle Sequencing Kit (Applied Biosystems), on an ABI 
3100 Genetic Analyzer (Applied Biosystems).           
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3.3 Antibody Constructs 
To produce lymphoma-derived antibodies, we designed and constructed two versatile expression 
vectors, one for the Ig heavy chain and another for the Ig light chain. These versatile expression 
vectors can be used for transient as well as stable transfection in mammalian cells. Recombinant IgH 
gene constructs consisted of a CMV promoter, a mouse Ig leader signal sequence, the rearranged 
IGVH gene from the respective SMZL, a human CH1 region, and mouse CH2-CH3-2b (Fc2b) 
region (supplemental Figure 1 in article II,). The mouse Fc2b constant region was chosen because of 
the readily available anti-IgG2b secondary antibodies necessary for in the various tests we performed. 
Recombinant Ig light chain constructs consisted of a CMV promoter, a mouse Ig leader signal 
sequence, the rearranged IGVL gene from the respective SMZL, and a human C region (supplemental 
Figure 1 in article II). The negative control construct contained only a mouse Ig CH2-CH3 2b 
fragment (Fc2b).  
The constructs for the heavy chains were made as follows: first, the IGVH PCR products were digested 
with BsmI and BsiWI restriction enzymes and inserted into a pLNOH2 vector that is a derivative of the 
pcDNA3 vector (Invitrogen), as described by Norderhaug (Norderhaug et al., 1997). Subsequently, the 
inserted IGVH gene together with an upstream leader signal sequence and the downstream human 
CH1 sequence from the pLNOH2 vector were amplified using a forward primer (5-CCG GGG GAT 
CCT CAC CAT GGG ATG GAG CTG TAT-3) and a reverse primer (5-TGT GGA TCC TTT GTC 
ACA AGA TTT GGG CTC-3). This PCR fragment was then inserted in-frame in a pcDNA1-Fc 
expression vector (Aasheim et al., 2000) between the upstream CMV promoter and the downstream 
mouse CH2-CH3-2b gene sequence. The constructs for the light chains were made by inserting the 
IGVL gene fragment into a variant of the pLNOH2 vector containing a CMV promoter, a mouse Ig 
leader sequence, and a human Ck sequence (Norderhaug et al., 1997).  
 
3.4 Transformation of bacterial cells 
Transformation is a technique to introduce DNA into bacterial cells, whereas the term transfection is 
typically used when the process is performed in mammalian cells. Depending on the type of cells to be 
transformed and the characteristic of DNA to be introduced, there are a number of transformation 
methods that can be applied including direct uptake, electroporation and microprojectile bombardment. 
Direct uptake of relatively small molecules is the simplest method to transform Escherichia  coli (E. 
coli )  and can be achieved by adding the construct to bacterial competent cells at a slightly elevated 
temperature followed by rapid chilling down in an ice-bath. The cells are then grown in medium with 
MgSO4 and MgCl2.. In article II, IgH and IgL constructs were transformed into TOP10 competent E. 
Coli cells (Invitrogen). For each lymphoma case at least 10 clones were selected for mapping and 
sequencing. Only the plasmids containing IgV sequences that were identical with the patient IgV 
sequences were used for transfection.  
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3.5 Transfection of mammalian cells 
Several methods are used to deliver the desired DNA/plasmids into eukaryotic cells: a biochemical 
method in which chemical carriers such as cationic lipids or calcium phosphate are used; a physical 
method where electroporation, microinjection or gene gun are applied and finally, a virus-mediated 
transduction method in which adenoviruses and retroviruses are used as vectors to deliver large 
amount of DNA into the host cell.  
Two transfection approaches can be used to transfer DNA/plasmid into cells, namely transient 
transfection and stable or permanent transfection. In transient transfection, plasmid is introduced into 
cells in order to achieve a temporary but high expression of the target gene. The transfected DNA does 
not necessarily become integrated into the genome of the host cell with this technique.  
In contrast, stable or permanent transfection is usually employed to establish clonal cell lines were the 
transfected DNA is integrated into the genome of the recipient cell line. The production levels of the 
recombinant protein following permanent transfection is usually lower than that of transient 
transfection.  
In article II, we were interested in the production of relatively large amounts of a panel of recombinant 
antibodies, and therefore, transient transfection was the method of choice. Two constructs carrying the 
respective IgH and IgL genes were co-transfected into HEK293T-cells by using lipofectAMINE 
transfection reagents (Invitrogen). The HEK293 cell line is relatively easy to transfect with the 
lipofectAMINE method and produces high quality recombinant proteins. HEK293T cells were grown 
in DMEM media (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal calf serum at 37º C in 
a humidified atmosphere with 5% CO2. The recombinant antibodies were purified from culture 
supernatant by using protein-A affinity chromatography. The concentration of the purified 
recombinant proteins was determined by the Bradford assay and the quality of the protein products 
was confirmed by SDS-PAGE and western blotting with mouse anti-IgG antibody. The yield of the 
respective recombinant antibodies were satisfactory (0.3 g/mL) except for one case, case 255 in 
article II, for which the production was very low compared to other cases despite several optimization 
attempts.  In one case, case 152, we found two different expressed VL genes; hence, we produced two 
different monoclonal antibodies using the same heavy chain and either of the two light chains genes, 
respectively.  
 
3.6 Flow cytometry 
Flow cytometry (FCM) is an established method for the immunophenotypical characterization of cells, 
and is extensively used in research and clinical settings. Flow cytometry was used in articles II and V. 
In article II, flow cytometry was used to detect whether the recombinant antibodies bound to auto-
antigens. Several cell lines, bone marrow aspirate and peripheral blood samples as well as lymph node 
cell suspensions were analyzed. Apoptosis assays were also performed to test whether the reactivity of 
the lymphoma-derived recombinant antibodies increased in apoptotic induced cell lines. Apoptosis 
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was induced in Jurkat and ovarian carcinoma cell line OVCAR-8 using the alkaloid staurosporine, 
which is known to induce apoptosis through both caspase-dependent and caspase-independent 
mechanisms. The apoptotic assay was performed as described previously in detail by Chu and Dong 
(Chu et al., 2010; Dong et al., 2008).   
Briefly, the sample cells to be analyzed by flow cytometry were suspended in a solution of 100 mg/ml 
human -globulin in dilution buffer (PBS with 1% BSA and 12.5 mM Na-Azide) and incubated with 
antibodies (30 μg/ml) at 4°C for 30 min before staining with phycoerythrine(PE)-linked goat anti-
mouse. To examine whether the recombinant antibodies reacted with potential antigens on the cell 
surface, the cells were pretreated with Trypsin EDTA solution containing 0.5 mg/mL trypsin and 
0.22mg/mL EDTA for 30 minutes at 37º C. The control cases were incubated only with PBS before 
staining. To investigate whether the recombinant antibodies bound to glycosylated epitopes, the cell 
cultures were incubated overnight with 1g/mL of tunicamycin (Sigma-Aldri), known to inhibit N-
glycosylation or were pre-treated with 5 units of N-glycosidase and 10 units of O-glycosidase (Roche 
Diagnostics ) before staining with the recombinant antibodies.  
In article IV, flow cytometry was used to characterize B cells in the bone marrow and blood from 
patients with DLBCL. This was done by using a panel of antibodies reactive with B lymphocyte 
surface antigens. Bone marrow aspirates and blood samples were analysed by a stain, lyse and wash 
method that has been previously described (Rothe and Schmitz, 1996). After pre-treatment, the cells 
were stained with a panel of commercially obtained primary monoclonal antibodies directly 
conjugated to fluoresceine thyocyanate (FITC), phycoerythrine (PE), phycoerythrinecyanine 5 
(PeCy5), peridinin chlorophyll protein (PerCP), peridinin chlorophyll protein-cy5.5 (PerCP-Cy5.5) or 
allophycocyanin (APC). Not all markers could be performed on all samples because of the number of 
cells available for analysis was limited in some samples.  
Flow cytometry analysis was performed on a FACSCalibur flow cytometer (Becton Dickinson, 
Heidelberg, Germany) and flow data were analyzed using software programs CellQuest 3.3 (BD 
Biosciences) and FlowJo 7.2.2 (Tree Star, Ashland, OR, USA). A total number of 10000 or more gated 
events were analyzed in each sample.  
 
3.7 Immunohistochemistry  
Immunohistochemistry (IHC) is used to detect the presence of antigens in cells of a tissue section. It is 
widely used both in clinical diagnostics as well as in basic research. Antigen-antibody interactions are 
visualized and examined in a microscope, therefore IHC provides information about the distribution 
and localization of antigens in tissues and cells. Experimental parameters such as the specificity and 
the amount antibody used, fixation, antigen retrieval steps as well as well as subjectivity of 
interpretation may influence the results achieved in IHC staining (Fritschy, 2008). These parameters 
were therefore controlled where possible. 
 37
In article I, immunohistochemistry was performed on paraffin-embedded tissue sections from ten 
lymph nodes to analyze monocytoid B cell in their microenvironment. Immunohistochemistry was 
also performed on frozen tissue sections of two lymph nodes, in order to select monocytoid B cells for 
micro-dissection and PCR analysis. Either the peroxidase-labeled ready-to-use EnVision+ Systems 
(DakoCytomation, Glostrup, Denmark) or double staining was carried out using a combination the 
EnVision+ Systems and biotin-streptavidin-peroxidase complex method (ABC) according to the 
instructions of the manufacturers. Table 4.1 summarizes the anti-bodies used in this study, their source 
and their respective distribution and function in tissues and cells.  
 
Antibody  Supplier Distribution in normal tissue Function 
CD3 Novocastra thymocytes, peripheral T cells; CD3 is a pan T-cell 
marker 
member of immunoglobulin superfamily 
CD4 Novocastra T helper cells (80-90%), granulocytes, 
macrophages, dendritic cells 
serves as co-receptor in MHC class II-restricted 
antigen induced T cell activation 
CD8 Novocastra cortical thymocytes, mostly cytotoxic T cells, NK 
cells dendritic cells 
recognizes antigens displayed by an antigen 
presenting cell (APC) 
CD21 Novocastra mature B cells, follicular dendritic cells, some 
thymocytes, some T cells 
part of the B cell co-receptor complex and  
participates in B cell response to the antigen 
CD23 Dako activated mature B cells expressing IgM or IgD, 
activated monocytes / macrophages, T cell subsets, 
platelets, eosinophils, follicular dendritic cells 
acts as a B cell growth and activation factor, 
promoting differentiation into plasma cells  
CD27 Dako memory B cells, NK cells, plasma cells, medullary 
thymocytes and some  T cells 
regulates B cell activation and immunoglobulin 
synthesis, marker of T cell activation 
CD35 Dako erythrocytes, basophils, eosinophils, granulocytes, 
monocytes, macrophages (some), B cells, T cells 
(10%), NK cell subset; CD35 is  a dendritic cell 
marker 
binds immune complexes coated with C3b or 
C4b and mediates their transport to and removal 
by the fixed phagocyte systems of the spleen and 
liver 
CD40 Dako mature B cells, dendritic cells, macrophages, mast 
cells, activated monocytes, platelets 
plays a central role in germinal center formation, 
in T-cell mediated immunity and mediates 
immunoglobulin class switching and the B cell 
memory cell development  
AID H.Niedobitek  B cells activation-induced cytidine deaminase, essential 
for immunoglobulin somatic hypermutation and 
class-switch 
BCL2 Dako many cell types member of the B-cell lymphoma 2 large family 
of proteins that regulate and contribute to 
programmed cell death or apoptosis 
BCL6 Dako activated B cells (germinal centers) represses genes that function in lymphocyte 
differentiation, inflammation and cell cycle 
control 
IgD Dako mature B cells is one of the BCR isotypes; participates antigen 
binding and BCR signal transduction 
Ki-67 Dako multiple tissues; proliferation marker plays a role in  cell proliferation; essential for 
cell cycle progression 
 
Table 4.1: antibodies used for immunohistochemistry in article I 
 
In article II, immunohistochemical analysis was performed using the peroxidase-labeled ready-to-use 
EnVision+ Systems (DakoCytomation, Glostrup) according to the instructions of the manufacturer. 
The formalin-fixed and paraffin-embedded tissues as well as cell-blocks from human pancreatic 
carcinoma cell lines MIA PaCa-2 and PANC-1 were cut at 4-5 μm, dried at 60 º C  overnight, then 
stored in a fridge at 4-8  º C  until used. Subsequently, the sections were stained with lymphoma-
derived recombinant antibodies as primary antibodies. The recombinant antibodies reacted diffusely 
with ubiquitous antigenes in the cytoplasm and to a lesser degree on the membrane of cells, indicating 
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poly- and self reactivity. Negative controls were incubated with either the Fc2 protein or only 
washing-buffer instead of primary antibodies. The scoring was assessed by an experienced pathologist.  
In article IV, immunohistochemical staining was performed on diagnostic biopsies from patients with 
primary diffuse large B-cell lymphoma without evidence of concurrent non-Hodgkin’s lymphoma as 
well as on bone marrow trephine biopsies. Commercially obtained primary antibodies (table 4.2) and 
peroxidase-labeled ready-to-use EnVision+ Systems (Dako) were used according to the 
manufacturer’s instructions. 
  
Antigen Supplier Distribution in normal tissue Function 
 
CD5 Novocastra, thymocytes, almost all T cells, subset of mature B 
cells 
negative regulator of  TCR and BCR signaling 
 
CD10 Novocastra  Early-B and T-cell precursors and subset of mature 
B cells including germinal centers 
zinc-dependent cell-surface metallopeptidase 
that cleaves peptide bonds on the amino side of 
hydrophobic amino acids, plays a role in B-cell 
differentiation 
CD20 Novocastra  pan B-cell marker  but absent in plasma  cells  plays a role in creation of  a structure similar to 
an ion channel that allows for the influx of 
calcium required for cell cycle activation 
CD23 Novocastra  activated mature B cells expressing IgM or IgD, 
activated monocytes /macrophages, T-cell subsets, 
platelets, eosinophils, follicular dendritic cells 
acts as a B-cell growth and activation factor, 
promoting differentiation into plasma cells 
CD30 Dako ativated B, T and NK cells, monocytes, ranulocytes 
and some plasma cells 
member of tumor necrosis factor family, 
activates  expression of nuclear factor-KB 
CD138 Dako and /or 
Lab Vision,  
B cell precursors, plasma cells, stratified squamous 
epithelium 
mediates cell adhesion, growth factors, 
associated with late stage of B cell 
differentiation 
BCL2 Dako multiple cell types member of B-cell lymphoma 2 protein family 
that contribute to programmed cell death or 
apoptosis 
BCL6 Dako activated B-cell lymphocytes in the germinal center represses genes that function in lymphocyte 
differentiation, inflammation, and cell cycle 
control 
Ig Dako mature and immature B cells is the light chain domain of the immunoglobulin 
protein; BCR antigen binding and signal 
transduction 
Ig Dako mature and immature B cells is the light chain domain of the immunoglobulin 
protein; BCR antigen binding and signal 
transduction 
IgD Dako mature B cells is one of the BCR isotypes; participates in 
antigen binding and BCR signal transduction  
IgM Dako mature and immature B cells is one of the BCR isotypes; participates in 
antigen binding and BCR signal transduction 
Ki-67 Dako multiple tissue, a proliferation marker plays a role in  cell proliferation and is essential 
for cell cycle progression 
MUM1 Dako cells of lymphocytic and melanocytic lineages; 
absent in centroblasts but upregulated in a subset of 
centrocytes and plasma cells 
MUM1 (multiple myeloma oncogene 1)/IRF4 
(interferon regulatory factor 4); plays important 
roles in cellular proliferation and survival 
Cyclin D1 Lab Vision,  multiple tissues cyclin D1 a proto-ongogen; plays a role in 
inactivatition of the retinoblastoma protein and 
promotes progression through the G1-S phase of 
the cell cycle 
 
Table 4.2:  antibodies used for immunohistochemistry in article IV 
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3.8 Western blot and enzyme-linked immunosorbent assay  
In addition to IHC, reactivity of the recombinant antibodies was tested by WB and ELISA analysis in 
article II. WB is a useful method to detect the presence and relative amounts of the protein present in 
different samples, the relative molecular weight (MW), posttranslational modifications of the protein 
of interest as well as protein-protein interactions. Despite many protocol modifications and new 
technologies to increase the sensitivity and speed of the method, experimental conditions still require 
optimizing. Cell lysis conditions, the quality and quantity of the loaded protein, antibody specificity 
and concentration, the type of the membrane used, the number of times washed, the incubation and 
exposure time are among the factors that can influence the accuracy of WB results (MacPhee et al., 
2010). The Enzyme-Linked Immunosorbent Assay (ELISA) is another technique used for the 
detection of a protein in a sample based on an immunological reaction. The ELISA method offers two 
major advantages compared to WB. ELISA is more suitable for screening a large number of samples 
and provides better quantitative data.  
In article II, total cell lysates from four different cell lines, MIN6, HEK293T, HEP-G2 and HELA 
were analyzed by WB. In brief, cell pellets were washed twice in phosphate-buffered saline (PBS), 
lysed in appropriate lysis buffer supplemented with inhibitor cocktails targeting phosphatases and 
proteases, and clarified with centrifugation. 25 g of the cell lysate in sample buffer with DTT was 
resolved by SDS-PAGE, and the separated proteins were transferred to a PVDF membrane. To verify 
even loading of the proteins on the gel and successful transfer of the proteins to the membrane, the 
membrane was stained with a naphthol–blue black solution. Blocking agents were used to reduce 
unspecific antibody binding in immunoblotting. First, we used non-fat dry milk in PBS 0.1 % tween as 
a blocking agent. Since as we observed that the recombinant antibodies bound to epitopes in milk, 
blocking was subsequently performed with 5% BSA bovine serum albumin in PBS 0.1 % tween. After 
blocking, the membrane was incubated overnight at 4°C with 3 g/mL of the respective recombinant 
antibodies, washed with PBS 0.1 % Tween and incubated with horseradish peroxidase-conjugated goat 
anti-mouse secondary antibodies. Enhanced chemiluminescence (ECL) ready-to-use-kit (GE 
Healthcare, Fairfield, CT, USA) was used to visualize antibody binding. Recombinant Fc2 fragment 
was used instead of a primary antibody for control experiments.  
 
To validate the polyreactivity of the lymphoma-derived recombinant antibodies, indirect ELISA 
analyses were performed. Crude cell lysates of HEK293T and PANC1 were prepared as described for 
Western analysis. A panel of proteins including thyroglobulin (TG), 	-galactosidase, insulin, 
lipopolysaccharide (LPS) human serum albumin (HSA), BSA as well as single strand DNA (ssDNA), 
either purchased from commercial suppliers or obtained as gift, were tested with the respective 
recombinant antibodies in ELISA. HRP-linked rabbit anti-mouse Ig was used as secondary antibody. 
Fish-skin gelatin (Sigma-Aldrich) was used as blocking agent as we found that our monoclonal 
recombinant antibodies bound to some degree to coated BSA. Appropriate positive and negative 
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control runs using either the recombinant Fc2 protein (homemade), a mouse monoclonal IgG2b-E149 
specific for neuron-specific enolase or mouse monoclonal anti-TG IgG1(E41) antibody specific to 
thyroglobulin (TG) (kind gifts from Dr Elisabeth Paus, Medical Biochemistry Department, the 
Norwegian Radium Hospital), were included in all ELISA experiments.            
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4. Results in brief 
 
4.1 Article I: Monocytoid B cells: an enigmatic B-cell subset showing evidence of  
extrafollicular immunoglobulin gene somatic hypermutation 
The presence of somatically hypermutad immunoglobulin VH genes in patients with hyper IgM 
syndrome and X-linked lymphoproliferative diseases, conditions that are characterized by the absence 
of germinal centers, raises the question whether somatic hypermutation and clonal expansion might 
take place in micro-anatomical sites outside the germinal center. We investigated whether somatic 
hypermutation might be acquired in the monocytoid B cell-zone. Monocytoid B cells are a B-cell 
subset localized in the perisinusoidal area of the lymph node and can be recognized in certain reactive 
lymph node and lymphoma conditions, including lymphadenitis caused by toxoplasma and HIV 
infections (Miettinen, 1981; Mohrmann et al., 1991). The ontogeny and function of monocytoid B 
cells is poorly understood. It has been suggested that monocytoid B cells are closely related to 
marginal zone B cells (De Wolf-Peeters et al., 1997; Tierens et al., 1999). Accordingly, nodal marginal 
zone cells may display the morphology of monocytoid B cells (Nathwani et al., 1999; Swerdlow, 
IARC Press, Geneva, 2008).  
Whether monocytoid B cells are post-germinal center B cells or whether these acquire IGVH gene 
somatic hypermutations outside the germinal center had yet not been investigated. To address this, we 
performed a detailed analysis of clonal expansion, SHM profile rearranged immunoglobulin gene and 
investigated expression of activation-induced cytidine deaminase (AID) in monocytoid B cells.  
Results of the immunohistochemical analysis showed that monocytoid B cells co-express AID and the 
proliferation-associated marker Ki-67, conditions that are prerequisites for somatic hypermutation and 
clonal expansion, respectively. We observed that monocytoid B cells microdissected from defined 
extrafollicular areas shared mutated IGVH genes confirming clonal expansion. Importantly, ongoing 
somatic hypermutation was demonstrated. 
The expression of AID as well as the presence of on-going mutations in proliferating monocytoid B 
cells provides evidence that somatic hypermutation occurred in situ in the perisinusoidal area of the 
lymph node, where the monocytoid B cells are located. Hence our results indicate that somatic 
hypermutation may occur outside the germinal center, and as consequence, that the presence of 
somatic hypermutation not necessarily indicates a germinal or post-germinal center cell origin.  
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4.2 Article II: Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses 
poly- and self-reactive antibodies with similar reactivity 
About 30% of SMZL shows a rearranged VH1-02 IgVH gene, suggesting that SMZL arises from a B 
cell that has been selected by an antigen. The objective of this study was to determine the antigen-
specificity and reactivity of antibodies expressed by SMZL that display a rearranged VH1-02 gene. 
This information is part of a study that seeks to investigate antigen stimulation in SMZL pathogenesis. 
First, we characterized IGVH and IGVL genes of 10 SMZL patients. The complementarity determining 
regions 3 (CDR3) of the IGVH and IGVL genes were also analyzed. Interestingly, we found mutated 
IGVH  and IGVL genes in all of the cases. 6 of 10 cases revealed rearrangement of the VH1-02*04 
gene, and 7 of the 10 cases including, 5 cases with VH1-02*04 genes, also rearrange the HD3-3*01 
gene. In addition, the amino acid sequence analysis of the CDR3 regions of the cases with the VH1-
02*04 and HD3-3*01 genes showed remarkably homologous sequences. The CDR3 region is 
determining for antibody binding. Amino acid sequence alignment of the CDR3 regions from this 
study with those from previously published cases of SMZL with VH1-02*04 rearrangement showed 
similar CDR3 properties. This indicates that the antibodies produced by SMZL with VH1-02*04 gene 
rearrangement bind similar epitope(s).  
IGVH and IGVL genes from 5 SMZL cases with VH1-02*04 gene rearrangement were amplified and 
cloned into appropriate expression vectors. Subsequently, lymphoma-derived recombinant monoclonal 
antibodies of these cases were produced in vitro. The reactivity and specificity of those antibodies 
were tested by flow cytometry, immunohistochemistry, Western blotting and Enzyme-linked 
immunosorbent assay (ELISA). Of interest, 4 of the 5 recombinant antibodies showed similar 
reactivity. Poly- and self-reactivity was demonstrated with cytoplasmic, nuclear as well as cell surface 
antigens in a wide range of cell types, such as epithelial cells from different organs, mesenchymal cells 
including smooth muscle cells, lymphoid cells as well as macrophages. In addition, these lymphoma-
derived recombinant antibodies reacted also with epitopes in milk and in serum. Furthermore, Western 
blotting revealed that the antibodies recognized multiple proteins. The polyreactivity of the antibodies 
was further confirmed by ELISA. The recombinant antibodies showed strong but variable binding to a 
panel of antigens including thyroglobulin (TG), 	-galactosidase, insulin, lipopolysaccharide (LPS) 
human serum Albumin (HSA), BSA and single strand DNA (ssDNA). Of interest, antibody reactivity 
to antigens expressed on the cell surface induced by apoptosis was not demonstrated, in contrast to 
findings by others in chronic leukemia cases with VH1-02 gene rearrangement (Lanemo et al., 2008; 
Chu et al., 2010). Our results demonstrate that SMZL using the VH1-02*04 gene express polyreactive 
antibodies that react with common ubiquitous auto-antigens. This major subset of SMZL arises 
therefore likely from polyreactive B cells. Polyreactive B cells may be important as the first line of 
defense against infectious agents before an antigen-selected response can be mounted.  
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4.3 Article III: Few CD79B and MYD88 mutations in splenic marginal zone lymphoma  
NF-B is a transcription factor that plays a key role in the survival and proliferation of many kinds of 
B-cell tumors, including SMZL. Signaling from antigen receptors such as BCR, TCR, TLR, 
interleukin-1, CD40 and TNF receptor activates the canonical NF-B pathway. Signaling from the 
B-cell activating factor (BAFF) receptor and CD40 leads to activation of the alternative NF-B 
pathway. Genetic aberrations and various mutations in genes activating the NF-B signaling pathway 
have been identified in several B-cell NHL subtypes, including DLBCL with an activated B-cell 
immunophenotype. Constitutive activation of NF-B in these lymphomas contributes to lymphoma 
cell survival and proliferation. Since our results (see article II) indicate that antigen stimulation plays a 
role in SMZL lymphomagenesis, we investigated the occurrence of activating somatic mutations in 
genes of the NF-B pathway in SMZL. Ten samples of SMZL and 13 control cases of other MZL 
types were subjected to DNA sequence analysis of CD79A, CD79B, CARD11 and MYD88 genes. 
These genes contribute to the activation of the canonical NF-B pathway. We detected a point 
mutation in the CD79B gene (Y196H) of one of the SMZL cases. Additionally, one point mutation 
was identified in the MYD88 gene (L265P) of another SMZL case. No mutations were discovered in 
CD79A or CARD11 genes in SMZL cases. As expected from previous publications, no mutations were 
identified in the other MZL control cases. Interestingly, the missense mutation detected in CD79B in a 
SMZL case has been previously reported in the ABC subtype of the DLBCL (Davis et al., 2010). This 
mutation results in the substitution of the first tyrosine, which is known to be phosphorylation site in 
the ITAM region, with another amino acid, histidine in our case, leading to constitutively active BCR 
signaling and activation of the canonical NF-B pathway. Equally interesting, the L265P point 
mutation in MYD88, which we detected in onother SMZL case, has also been detected in 9% of 
gastric MALT lymphomas as well as in 29% of ABC DLBL by Davis et al. This mutation occurs at an 
amino acid residue which is functionally critical in the MYD88 mediated NF-B and JAK-STAT 
signaling pathways (Ngo et al., 2011). Indeed, the mutation is found in a highly conserved domain of 
the MYD88 gene in all mammalians and the L265P point mutation in MYD88 can cause three 
dimensional change of the MYD88 protein, leading to a protein complex that spontaneous triggers the 
phosphorylation of IRAK1 and  NF-B activation as a consequence (Ngo et al., 2011).   
The identification of mutations in CD79B and MYD88 genes in some SMZL cases represents 
additional genetic aberrations of signaling genes that may contribute to the constitutive activation NF-
B. Although few mutations were detected, the results provide evidence that chronic antigen 
stimulation likely is important for SMZL pathogenesis. However, continuous stimulation through 
(auto) antigen binding of the BCR is likely of more importance than activating mutations of NF-B 
pathway genes. 
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4.4 Article IV: Low levels of monoclonal small B cells in the bone marrow of patients with 
diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type 
The objective of this study was to investigate the occurrence of monoclonal small B cells (MSBCs) in 
the bone marrow of diffuse large B-cell lymphoma (DLBCL) patients and to establish a possible 
clonal relationship between DLBCL B cells and MSBC in the marrow. DLBCL represents about 30% 
of all adult non-Hodgkin’s lymphoma. The largest entity of this lymphoma is DLBCL not other-wise 
specified (NOS), which comprises two molecular distinct subtypes based on gene expression profiling; 
a germinal center B-cell-like (GCB) subtype and activated B-cell-like (ABC) subtype. In addition to 
DLBCL-NOS, other variants of DLBCL are recognized; primary cutaneous DLBCL of leg-type, 
primary DLBCL of central nervous system (CNS), primary testicular DLBCL, primary mediastinal B-
cell lymphoma (PMLBCL), T-cell/hystocyte-rich B-cell lymphoma (T/HLBCL) and double hit B-cell 
lymphoma with BCL-2 and C-MYC gene translocations (DHBCL). 
We investigated the presence of MSBCs in the bone marrows of 165 patients with primary DLBCL 
without histological evidence of concurrent non-Hodgkin’s lymphoma. The study was performed by 
multiparameter flow cytometry on bone marrow aspirates combined with morphological examination 
and immunohistochemical analysis of bone marrow aspirates and bone marrow trephine biopsies.  
DLBCL infiltration in marrows was detected in 11 cases of 165 patients (6.7%).  Of note, only 3 of 
119 cases with DLBCL NOS showed bone marrow infiltration. By contrast, flow cytometry analysis 
combined with morphological analyses revealed the presence of MSBCs in 24 of 165 cases of DLBCL. 
Strikingly, we observed a significant different frequency of the MSBC occurrence among the different 
DLBCL subtypes. Of the 119 patients with DLBCL NOS, 11 of 39 (28.2 %) of cases with ABC and 
only 3 of 80 (3.7%) cases with GCB subtype showed MSBC in the marrow (P = 0.0002). Whereas, the 
presence of MSBC in the marrow was detected 4 of 8 (50%), 4 of 15 (26.7) and 2 of 3(66.7) patients 
with primary testicular, CNS and leg-type DLBCL, respectively. No MSBCs were found in marrows 
of patients with rare DLBCL subtypes, such as PMLBCL, T/HLBCL or DHBCL. MSBCs in 15 of 25 
cases showed a non-CLL-like immunophenotype, 3 cases a CLL-like immunophenotype whereas 6 
cases were unclassifiable. Because of lack of proper materials, we could not systematically investigate 
the clonal relationship between MSBC in the marrow and DLBCL. However, identical rearranged 
IGVH genes from MSBCs in the marrow and DLBCL tumor cells from the same patient were 
successfully identified in one case, suggesting that at least in this case MSBC and DLBC share a 
common cellular origin. In addition, monoclonal small B cells in the blood were detected in 4 of 5 
DLBCL patients with MSBCs in their bone marrow. In those 4 cases, MSBCs in the blood and small 
MSBCs in the marrow showed a similar immunophenotype.  
 
 
 
 45
The results from this study provide evidence that the ABC subgroup of the DLBCL NOS as well as 
some of the rare DLBCL subtypes with an ABC immunophenotype but not GCB DLBCL are highly 
associated with the presence of MSBCs in the bone marrow. Whether MSBCs in the bone marrow are 
precursors of the ABC subtype of DLBCL remains to be further elucidated.  
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5. Discussion 
B cells are prone to malignant transformation because molecular mechanisms that are normally used 
for antibody diversification to fight against pathogens can result in aberrant chromosomal 
translocations and oncogenic mutations. Of interest, upon malignant transformation, B-cell 
lymphomas frequently retain properties of their cell of origin. Therefore, better understanding of B-
cell lymphomagenesis requires knowledge of normal B-cell lymphopoiesis. In this regard, the first 
article of this thesis studies a hitherto enigmatic B-cell subset, the monocytoid B cells. This B-cell 
subset is likely the cell of origin for the subset of nodal marginal zone lymphoma. In a second article 
we provide evidence that splenic marginal zone lymphoma likely arises from chronic stimulation of 
auto- and poly-reactive B cells. In a third study, we demonstrate that only few activating mutations are 
found in the BCR pathway genes of marginal zone lymphoma, despite activation of NF-B. The latter 
is consistent with the hypothesis that marginal zone lymphoma shows no autonomic growth but is 
dependent on continued chronic antigen stimulation for growth. In a fourth study, we provide evidence 
that even diffuse large B-cell lymphoma with an activated B-cell phenotype, may arise from 
circulating small monoclonal B cells, with an immunophenotype reminiscent of germinal zone B cells. 
 
5.1 Somatic hypermutation and clonal expansion of monocyoid B cells  
The pattern of somatic hypermutation in IgV genes allows us to deduce the ontogeny of B-cell 
malignancies. It is widely accepted that somatic hypermutation and class switching are the hallmark of 
the T-dependent immune response and markers for memory B cells. There is also a general consensus 
that somatic hypermutation of the IgV genes principally takes place in germinal centers (MacLennan, 
1994; Rajewsky, 1996). However, recent reports proposed that somatic hypermutation can be T-
independent thought still occurring in the germinal center (William et al., 2002; Weller et al., 2004; 
Scheeren et al., 2008; Weill et al., 2009). 
To analyze whether somatic hypermutation may occur outside the germinal center, we examined 
clonal expansion, expression of AID and somatic hypermutation of IGVH genes in monocytoid B cells 
in the lymph node. Monocytoid B cells are poorly characterized B cells. They are mature B cells that 
typically are present in perisinusoidal area of the lymph node. These cells are especially prominent in 
certain infections such as toxoplasmosis or viral infections. Whether monocytoid B cells give rise to 
nodal marginal zone B-cell lymphoma (NMZL), also known as monocytoid B-cell lymphoma, has 
been suggested but is still debated. We and others have previously demonstrated that monocytoid B 
cells express rearranged immunoglobulin genes with somatic hypermutations in variable regions 
(Tierens et al., 1999; Lazzi et al., 2006). In article I, we showed that monocytoid B cells co-express 
AID and the proliferation-associated marker Ki-67, proteins required for the induction of somatic 
hypermutation and clonal expansion, respectively. The sequences derived from clusters of the 
proliferating B cells revealed intraclonal diversification of IGVH genes through on-going mutations.  
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IGVH gene mutational analysis showed characteristic features of somatic hypermutation, such as G/C 
mutation bias and the presence of deletions as well as a predominance of transitions over transversions. 
These findings suggest that monocytoid B cells acquire somatic hypermutations in situ, i.e. the peri-
sinusoidal area of the lymph node where these B cells were isolated from. Several studies have already 
suggested that somatic hypermutation may occur outside the germinal center both in the human and 
mouse (Weller 2004; Mao et al., 2004). Patients with hyper-IgM syndrome as well as patients with X-
linked lymphoproliferative disease, whom lack germinal centers, do possess IgM+IgD+CD27+ 
circulating B cells with somatically mutated IGVH genes suggesting that these B cells develop outside 
the germinal center (Chu et al., 1995; Weller et al., 2001; Weller et al., 2004). It has been proposed 
that IgM+IgD+ CD27+ B cells acquire somatic mutations during a primary, T-independent pre-
diversification process outside the germinal center, as demonstrated in sheep and rabbits (Reynaud et 
al., 1995; Weill et al., 2004). This proposal was also supported by the finding that murine immature B 
cells express somatically hypermutated IGVH as well as AID (Mao et al., 2004). Contrary to this view, 
it has been suggested that IgM+IgD+CD27+ B cells with mutated IGVH genes represent germinal 
center-derived memory B cells, because the majority of these B cells carry mutated BCL6, the master 
transcriptional regulator in germinal center B cells and known to be targeted by the somatic 
hypermutation machinery (Pasqualucci et al., 2003; Seifert and Kuppers, 2009). BCL6 is only 
expressed in the germinal center B cells and its expression is prerequisite for the acquisition of somatic 
hypermutation. 
Monocytoid B cells are a distinct B-cell population, but show some immunophenotypic similarity with 
circulating IgM+IgD+CD27+ B cells. Indeed, monocytoid B cells are IgM+IgD-CD27-/+. Whether 
circulating IgM+IgD+CD27+ B cells arise from monocytoid B cells is an interesting question that 
requires further study. 
Our data show that monocytoid B cells may not arise from germinal center or post- germinal center B 
cells, but may indeed acquire somatic mutations in another way. Whether these mutations are acquired 
during a pre-diversification process or whether mutations are acquired by T-cell or non-T-cell-
dependent antigen stimulation remains to be demonstrated. 
 
5.2 A subset of SMZL expresses IGVH genes with unique features 
Irrespective of the question where somatic hypermutation occurs in MZL, the vast majority of these 
lymphomas express IgM antibodies with mutated IGVH genes. Furthermore, this disease is strongly 
associated with chronic antigen stimulation (Suarez et al; 2006). Although the association between H 
pylori infection and extranodal marginal zone lymphoma MALT type is clinically and molecularly 
well characterized, the pathogenesis of SMZL and NMZL are as yet not well studied. However, 
antigen stimulation is believed to be important for the pathogenesis of these two latter entities as well. 
In article II, we studied, albeit indirectly, the possible role of antigenic stimulation in the SMZL 
development. First, detailed molecular analysis of the immunoglobulin gene variable regions was 
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performed in 10 well-characterized SMZL patients. Interestingly, 6 of those 10 cases used the same 
VH1-02*04 gene, while the remaining four cases used VH1-18, VH4-59 (two cases) and VH3-30 genes. 
At least three of the cases revealed intraclonal sequence variation caused by on-going mutations. 
Additionally, 7 of these 10 cases, including 5 cases with VH1-02*04 gene rearrangement, showed also 
usage of the same HD3-3*01 gene, whereas the other case with VH1-02*04 gene rearrangement used 
the HD3-9*01 gene which is highly homologous to the HD3-3*01 gene. However, no bias was 
detected in HJ segment use. Furthermore, the deduced amino acids of these 6 cases with VH1-02*04 
rearrangement showed highly homologous sequences with several conserved or semi-conserved amino 
acids and exceptionally long  CDR3 segments  with a relatively high isoelectric point (pI). Our results 
are quite similar to those that have been reported in previous studies, showing the preferential usage of 
VH1-02 gene rearrangement in SMZL (Algara et al., 2002; Tierens et al., 2003; Stamatopoulos et al., 
2004; Arcaini et al., 2009a). Of interest, there is apparent geographical variation with respect to the 
preferential usage of VH1-02 among different study cohorts with the fraction of cases using VH1-02 
rearrangement being remarkably low in the in the Greek series compared to other cohorts 
(Stamatopoulos  et al., 2004).  Very recently, a large study of 337 SMZL cases confirmed the 
preferential usage of the  VH1-02 gene rearrangement, mostly in combination with a HD3-3 gene 
rearrangement (Bikos et al., 2012). The characteristics of the CDR3 regions in SMZL with VH1-02*04 
rearrangement reported by Bikos’ group are very similar to those of the cases we studied (article II).  
A biased repertoire of IGVH genes is generally regarded as evidence for antigen selection involving a 
limited set of antigens or perhaps superantigens in B-cell lymphomagenesis (Stevenson et al., 2001; 
Kuppers, 2005). Several B-cell malignancies, most notably CLL and MCL are also characterized by 
both a biased IGVH usage as well as stereotyped CDR3 regions. Almost one-third of CLL samples 
show stereotyped BCRs, whereas 10% of MCL possess stereotyped BCRs (Stamatopoulos et al., 2007; 
Murray et al., 2008; Hadzidimitriou et al., 2011).  
Of interest, CLL cases with VH1-02 gene show different, short and stereotyped CDR3 sequences 
compared to SMZL cases with VH1-02 gene rearrangement (see article II, figure 1). The latter data 
suggest that the involved antigens in CLL are different than those in SMZL. The restricted 
immunoglobulin repertoire in SMZL implies that the antibodies expressed by SMZL B cells recognize 
common antigenic determinants. By consequence, these antigens very likely play a role in SMZL 
lymphomagenesis. 
 
5.3 SMZL-derived recombinant antibodies indicate involvement of antigen stimulation in SMZL 
pathogenesis  
To further characterize the binding activity of monoclonal antibodies (mAbs) expressed by SMZL 
cases with VH1-02*04 rearrangement, we synthesized recombinant antibodies derived from five cases 
of SMZL and tested their reactivity by several experimental approaches. Interestingly, 4 of the SMZL-
derived recombinant antibodies reacted similarly with a wide variety of cell lines as well as normal 
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and lymphoma tissues, whereas the fifth recombinant mAb failed to bind any antigen at all in all 
experiments that were performed. Cytoplasmic, nuclear as well as cell surface reactivity was detected 
in a wide range of cell types, but mostly in epithelial cells from different organs. Of interest, the 
recombinant antibodies reacted with multiple (auto) antigens. Remarkably, reactivity of the antibodies 
was drastically reduced or competitively blocked when these antibodies were pre-incubated or diluted 
with serum or milk, indicating that the antibodies also reacted with antigens that were present in milk 
and serum. Taken together, these results suggested that SMZL-derived recombinant antibodies were 
self-reactive and polyreactive. Polyreactivity of SMZL-derived antibodies was further evidenced by 
ELISA experiments that showed binding of the antibodies to a panel of purified antigens.  
Polyreactive antibodies comprise a large fraction of the early B-cell repertoire (Casali and Notkins, 
1989; Zhou et al., 2007). Nearly 75% and 55% of the early immature B cells of healthy human 
individuals express polyreactive and self-reactive BCRs, respectively (Wardemann et al., 2003), but 
most of these potentially harmful polyreactive auto-antibodies are eliminated from the repertoire at 
different checkpoints during early B-cell maturation. Thus only 5% of the naïve B-cell compartment 
retains polyreactivity (Tsuiji et al., 2006).  
Natural polyreactive IgM antibodies are likely important for the immediate immune defense against 
foreign antigens, such as viruses and bacteria, usually through T-cell independent immunity before 
more specific antibodies are generated. However, polyreactivity can also be detected in antibodies 
generated through T-cell dependent immunity. Polyreactivity of these antibodies might enhance 
antibody affinity for antigens where simple homotypic bivalent ligation is not achievable. 
Immunologic analysis of monoclonal anti-HIV-gp140 antibodies cloned from HIV patients revealed 
that the affinity of these antibodies for HIV-gp40 was improved through heteroligation to more 
abundant self-antigens, since homotypic bivalent binding is not feasible.  Thus, polyreactive anti-HIV-
gp 40 antibodies seem to be positively selected if they bind more strongly to HIV-epitopes than their 
monoreactive counterparts (Mouquet et al., 2011).
Although amino acid sequence alone cannot determine whether an antibody is polyreactive, the length 
of the Ig heavy chain CDR3 regions has been correlated with self-reactive and polyreactive antibodies 
(Ichiyoshi and Casali, 1994; Aguilera et al., 2001). Polyreactive anybodies usually have longer CDR3 
segments resulting in increased flexibility of the antigen-binding site with multiple configurations that 
allows the antibody to recognize a variety of structurally unrelated epitopes (Notkins, 2004). 
Accordingly, the CDR3 regions of our SMZL cases with VH1-02 rearrangement were unusually long. 
Also antibodies derived from other B-cell lymphoma types including some gastric MALT lymphoma, 
CLL with unmutated IGVH genes as well as HCV-positive SMZL revealed polyreactive features 
(Hamblin et al., 1999; Carbonari et al., 2005; Craig et al., 2010). Of interest, most of these lymphomas 
show VH1-69 gene rearrangement. VH1-69 encoded antibodies have been shown to display 
rheumatoid activity (Bende et al., 2005; Baecklund et al., 2006).  By contrast, the VH1-02 encoded 
antibodies in our study do not show rheumatoid activity.   
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Whether SMZL with the VH1-02 gene rearrangement arises from natural antibody producing B cells 
or from an antigen-selected post-germinal center B cell is yet to be clarified. The presence of somatic 
hypermutation in SMZL is in favor of the latter hypothesis. However, somatic hypermutation may also 
occur outside the context of the germinal center as we have demonstrated in article I, and therefore an 
origin from a natural antibody producing B cell is not excluded. Of interest, the major population of 
IgM+ cord blood B cells, about 20% shows VH1-02 gene rearrangements in contrast to circulating 
adult IgM+ B cells that mostly show VH3 gene rearrangements (Prabakaran et al., 2012). This may be 
indirect support for an origin of SMZL from natural antibody producing B cells. In addition, the 
preferential usage of the same VH1-02(*04) gene, the presence of somatic hypermutation, highly 
homologous CDR3 segments with distinctive features and similar pattern of polyreactivity strongly 
suggest a role for antigen/auto- antigen stimulation in lymphomagenesis in SMZL.  
 
5.4 Somatic mutations in NF-B pathway regulating genes in SMZL  
Up-regulation of the NF-B pathway genes as wells as its target genes have been observed in SMZL 
(Ruiz-Ballesteros et al., 2005). NF-B activation promotes proliferation and decreases apoptosis 
(Davis et al., 2010). The results from article II indicate that antigen stimulation may have contributed 
to SMZL lymphomagenesis. In study III of this thesis, we analyzed potentially oncogenic mutations in 
the BCR and MYD88 signaling. MYD88 is a cytosolic adaptor protein that contains an N-terminal 
death domain and a C-terminal Toll–IL-1R (TIR) domain separated by a short linker sequence. It plays 
crucial roles in both innate and acquired immune responses through signal transduction initiated by 
toll-like-receptors (TLRs) and various interleukin-receptors (Medzhitov et al; 1998). The activation of 
MYD88 signaling originates from interaction between the cytosolic TIR domain of the ligand-induced 
TLRs and the TIR domain in the MYD88 C-terminal. Upon stimulation, MYD88 recruits and activates 
IL-1-receptor associated kinase (IRAK) to the TLR-MYD88 complex, forming a TLR-MYD88-IRAK 
complex. In return, the TLR-MYD88-IRAK complex recruits and activates TNF receptor associated 
factor-6 (TRAF6) to the TLR-MYD88-IRAK complex, then activated TRAF6 mediates activation of 
down stream signaling pathways including NF-B (reviewed in Takeda and Akira, 2004).  
We detected a point mutation in the CD79B gene (Y196H) in one of the SMZL cases. Additionally, 
one point mutation was detected in the MYD88 (L265P) gene in another SMZL case. However, neither 
CARD11 nor CD79A were found mutated in these 10 SMZL cases. Furthermore, none of the 13 
control cases form non-SMZL MZL cases did demonstrate any mutations in the analyzed genes. 
Interestingly, the site where we detected mutation in the CD79B gene in SMZL has been previously 
described as one of the CD79B hotspot mutation motifs in the ABC subtype of DLBCL, and this 
mutation is detected in almost all of the mutated ABC DLBCL cases (Davis et al., 2010).  
While preparing our study III, Yan and colleagues reported mutations either in CARD11 (8.8%), 
TNFAIP3(13%) or MYD88 (13%) genes in SMZL. However, mutations in CD79A and CD79B genes 
were not detected in these SMZL cases (Yan et al., 2012). TNFAIP3 codes for the “global” NF-B 
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negative regulator A20, and is inactivated by mutations or epigenetic silencing in many lymphoma 
subtypes, including HL, PMBL and ABC DLBCl, and MALT lymphomas (Schmitz et al., 2009; 
Compagno et al., 2009; Kato et al., 2009).  
Activating somatic mutations in CD79A, CD79B, CARD11, MYD88 genes have been previously 
demonstrated in ABC DLBCL (Lenz et al, 2008; Davis et al., 2010; Ngo et al., 2011). More recently, 
in a study of 101 SMZL cases, Rossi et al. detected that more than one third of SMZL harbour 
mutually but exclusive somatic mutations in various regulators involved in the canonical (A20 and 
IKB-B) as well no-canonical  (BIRC3, TRAF3, MAP3K14) NF-B activation pathways (Rossi et al., 
2011).  
In conclusion, constitutional activation of NF-B through activating mutations also contributes to 
SMZL lymphomagenesis. Whether chronic antigen stimulation increases the risk of activating 
mutations is an interesting hypothesis but remains to be demonstrated. Of interest, activation of NF-B 
is also seen in the two other types of MZL, NMZL and extra-nodal MZL or MALT lymphoma, albeit 
through different genetic mutations. In MALT lymphoma several oncogene translocations 
t(1;14)(p22;q32), t(14;18)(p32;q21), t(11;18)(q212;21) result in constitutive activation of the NF-B 
pathway (reviewed by Du, 2011). Additionally, genetic lesions inactivating A20 have been detected in 
translocation-negative MALT lymphoma cases, particularly those from the ocular adnexa, salivary and 
thyroid glands, resulting prolonged NF-B activity (Kato et al., 2009; Bi et al., 2011).  
 
5.5 Monoclonal small B cells (MSBC) in the bone marrow of ABC DLBCL: are they precursor 
cells of this lymphoma? 
DLBCL accounts for about 30% of all adult non-Hodgkin’s lymphoma. The WHO lymphoma 
classification recognized several clinically and genetically distinct types of DLBCL (Swerdlow, IARC 
Press, Geneva, 2008). The largest entity is DLBCL, not other-wise specified (NOS). This lymphoma 
type is further subdivided into two subtypes with distinct gene expression profiling, germinal center B 
cell-like (GCB) and activated B cell-like (ABC) subtypes. These two subtypes have the expression 
signature of normal germinal center B cells and activated B cells, respectively (Alizadeh et al.; 2000; 
Rosenwald et al., 2002). The GCB subtype is associated with a better prognosis whereas the ABC 
subtype shows a worse outcome (Rosenwald et al., 2002). 
In article IV, we studied the occurrence of MSBC in the bone marrow of 165 consecutive patients with 
various DLBCL subtypes without histological evidence of concurrent NHL. 119 of these cases were 
DLBCL NOS type, whereas the rest of the cases were other types and subtypes of DLBCL. We 
detected MSBCs in 24 of 165 cases of DLBCL. Strikingly, the occurrence of MSBCs   in the bone 
marrow has been observed in 11 of 39 (28.2%) of cases of ABC subtype and in only 3 of 80 (3.7%) of 
GCB DLBCL subtype. Of note, clinical records of these cases did not show diagnosis of leukemia. 
The difference in incidence of MSBCs between ABC and GCB of DLBCL NOS was significant (P 
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value of 0,0002). Interestingly, of the 24 cases with MSBC cells in the marrow, 10 cases showed a 
discordant immunophenotype between MSBC and the respective DLBCL.  
MSBCs in the bone marrow of DLBCL patients are likely similar to those cells present in the 
peripheral blood of elderly people, also termed as monoclonal B-cell lymphocytosis (MBL) (Ghia et 
al., 2004; Marti et al., 2005). This is demonstrated in our study by showing that patients with MSBC 
displayed MBL in their blood with similar immunophenotype. 
MBL is defined as the presence of monoclonal B cells in the peripheral blood below 5000 cell/ L in 
the absence of small B-cell lymphoma (Hallek et al., 2008; Mowery and Lanasa, 2012). The etiology 
of MBL is still unknown. However, risk factors including aging, certain chromosomal abnormalities as 
well as inherited genetic variation in certain genes such as FARP2, IRF4 and SP140 have been 
associated with the MBL development (Rawstron, 2009; Crowther-Swanepoel et al., 2010). Antigen 
stimulation may also contribute to the clonal expansion of MBL, as it has been demonstrated that a 
high proportion of CLL-like MBL cases show somatically hypermutated IGVH genes (Rawstron, 
2009).  
MBL is heterogeneous in terms of immunophenotype and can be distinguished on the bases of CD5 
surface marker expression (Ghia et al., 2004). Only a minor fraction of MBL cases are CD5-negative 
(termed CD5- MBL), whereas the majority of MBL cases are CD5-postive (CD5+ MBL). CD5+ MBL 
cases can be further subdivided into two subtypes based on the expression level of CD20; a non-CLL-
like MBL subtype with bright CD20 expression and a CLL-like MBL subtype with low levels of 
CD20 expression (Marti et al., 2005). The latter subtype shares with CLL certain characteristic 
features including high expression of the CD23 surface marker and weak or no expression of CD79B 
as well as surface immunoglobulins. Most importantly, CLL-like MBL shares genetic feature with 
CLL. The CLL-like MBL subtype is the most frequent MBL type, especially among the elderly and 
can be detected in up to 7% of individuals older than 75 years (Ghia et al., 2004).  
Of interest, of 24 DLBCL patients with MSBC in their bone marrow, only 3 had MSBC with a CLL-
like immunophenotype, whereas 15 had MSBC with a non-CLL-like immunophenotype. The 
remaining 6 patients had MSBC with a non-classifiable immunophenotype. This is in contrast to the 
published frequencies of MBL immunophenotypes in normal population in which the CLL-like 
immunophenotype dominates (Ghia et al., 2004; Rawstron, 2009).  
We could not systematically investigate the clonal identities of MSBC and DLBCL because of lack of 
proper materials for this analysis. The analysis was attempted in 10 sample pairs of the bone marrow 
trephines and matched DLBCL biopsies that were available for analysis. Despite several attempts, 
immunoglobulin gene rearrangement analysis was only successful in one case (patient 11). The 
monoclonal B cells in this case showed a CLL-like immunophenotype. Interestingly, the rearranged 
IGVH genes of MSBC and the DLBCL tumor of this patient displayed an identical IGVH sequence, 
including the clone-specific CDR3 region, proving the similar clonal origin of MSBC and DLBCL. 
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The identification of MBL as a precursor lesion of CLL has been well documented in recent years and 
the MBL progression to CLL has been estimated a rate of 1.1% per year (Rawstron, 2009). However, 
the overwhelming majority of MBL does not progress to CLL.    
Our study demonstrates that at least some MSBC may progress to DLBCL. To understand the nature 
of MSBC in the bone marrow of DLBCL and MBL in the peripheral blood, we will prospectively 
collect bone marrow and the peripheral blood of DLBCL patients, isolate the MSBC  from the bone 
marrow and blood, perform genetic analysis and compare results with these obtained in  DLBCL. 
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6. Concluding remarks and future perspectives 
B-cell lymphomas arise from B cells at distinct stages of maturation and differentiation. The majority 
of SMZL carries mutated immunoglobulin genes and accordingly it has been postulated that SMZL 
originates from post-germinal center B cells. However, our data as well as that from others suggests 
that the somatic hypermutation process is not restricted to the germinal center micro-environment, as 
evidenced by somatic hypermutation occurring in monocytoid B cells in the perisinusoidal lymph node 
area. Therefore, the mere presence of somatic hypermutation in the rearranged immunoglobulin genes 
cannot be taken as final proof for germinal center or post-germinal center cell origin for B-cell 
lymphoma. Impact of somatic hypermutations on IGVH genes can be detected in about 87% of SMZL 
(Bikos et al., 2012). Irrespective of the maturation stage of its cell of origin, it can safely be assumed 
that somatic hypermutation is proof of antigen exposure in SMZL. Our study of SMZL confirms a role 
of antigenic stimulation in SMZL lymphomagenesis. In spite of the self and poly-reactive nature of 
SMZL-derived antibodies, reactivity with a defined external pathogen, perhaps infectious, is not 
excluded. Infections have been demonstrated in various MALT lymphoma subtypes. The search for an 
infectious origin of SMZL should therefore be continued. 
Similar to several other B-cell lymphoma types, SMZL lymphoma is characterized by oncogenic 
mutations that constitutively activate the NF-B signaling pathway (Compagno et al., 2009; Lenz et al, 
2008; Davis et al., 2010; Ngo et al., 2011), and we identified some additional potentially oncogenic 
mutations affecting that pathway. The identification of such mutations may lead to the development of 
targeted therapies for patients suffering from SMZL.  
Finally, we found the presence of MSBC in the bone marrow of a large fraction of patients with the 
ABC subtype of DLBCL NOS but not of GCB subtype of DLBCL NOS. This finding provides further 
evidence that the ABC and GCB DLBCL subtypes have distinct pathogeneses. At least in one ABC 
DLBCL case, the rearranged IGVH gene of the monoclonal small B cells and the respective tumor 
biopsy showed identical IGVH gene sequences, indicating that MSBC may be a direct precursor of the 
ABC subtype of DLBCL. However, the relationship between MSBC and the ABC DLBCL needs to be 
further investigated. We hypothesize that MSBC arise through chronic antigen stimulation, may 
acquire oncogenic mutations and ultimately lead to the development of ABC DLBCL. This hypothesis 
will require future studies. 
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                                         ERRATA 
 
A) Typographical errors; 
1. page 8, line 6; changed from  associated  tissue to associated  lymphoid tissue 
2. page 8, line 7; changed from b-cell to B-cell 
3. page 9, after line 14; a new line containing “accepted for publication: ISRN-Oncology, 2013” 
is inserted:   
4. page 11, line 19; changed from occupy he dark zone to occupy the dark zone 
5. page 13, line 20; changed from the D-JH point to and the D-JH fragment 
6. page 16, line 2; changed from CD40-dificient to CD40-deficient 
7. page 19, line 2; changed from fraction monocytoid to fraction of monocytoid 
8. page 23, line 1; changed from examples of translocations to examples of these translocations 
9. page 24, line31; changed from (ITAMS) to (ITAMs) 
  
B) Reference numbering in article 3 (Few CD79B and MYD88 mutations in splenic marginal zone 
lymphoma), the following number corrections were made.  
Page 3, line 7; changed from18 to 15 
Page 3, line 9; changed from 15 to 16 
Page 4, line 3; changed from 13 to 14 
Page 5, line 7; changed from 16 to17 
Page 5, line 8; changed from 17 to15 
Page 5, line 11; changed from 15 to16 
 
 C) References and the reference list of the thesis manuscript were corrected. 
In the main text, the names of authors are now corrected (for instance, La-Favera ( Riccardo Dalla-
Favera) is changed to Dalla-Favera, Van Den Oord is changed to van den Oord or Maclennan is 
changed to MacLennan, etc). References from the reference list that were not referred to in the main 
text are now added to the latter, and vice versa. 
 69

I

II

III

Few CD79B and MYD88 mutations in splenic marginal zone lymphoma. 
Gunhild Trøen1, Abdirashid Warsame1 and Jan Delabie1,2.
1Department of Pathology, The Norwegian Radium Hospital,  Oslo University Hospital, Oslo, 
Norway and 2Faculty of Medicine, University of Oslo, Oslo, Norway.
Key words: mutations, NF-B signaling, lymphoma 
Corresponding Author: 
Gunhild Trøen, PhD 
Department of Pathology 
The Norwegian Radium Hospital, Oslo University Hospital 
0310 Oslo, Norway 
GTO@ous-hf.no
Phone: +47 22934180, Fax: +47 22508554
Abstract
In this study we have examined the mutation status of genes involved in the NF-B signaling 
pathway. DNA sequence analysis of four genes was performed: CD79A, CD79B, CARD11 
and MYD88 that are activated through BCR signaling or Toll-like and interleukin signaling. 
A single point mutation was detected in the CD79B gene (Y196H) in one of ten SMZL cases. 
Additionally, one point mutation was identified in the MYD88 gene (L265P) in another 
SMZL case. No mutations were revealed in CD79A or CARD11 genes in these SMZL cases. 
Neither were mutations detected in these four genes studied in 13 control MZL samples. 
Interestingly, the two cases with mutations of CD79B and MYD88 showed increased numbers 
of immunoblasts spread among the smaller and typical marginal zone lymphoma cells. 
Although SMZL shows few mutations of NF-B signaling genes, our results indicate that the 
presence of these mutations is associated with a higher histological grade. 
Introduction 
Marginal zone lymphoma (MZL) is a non-Hodgkin lymphoma that likely develops from B-
lymphocytes in the marginal zone of secondary lymphoid tissue. There are three subtypes of 
marginal zone B-cell lymphoma (MZL)1 : nodal, extra-nodal and splenic marginal zone 
lymphoma, arising in the lymph node, mucosa and the spleen, respectively. Splenic marginal 
zone lymphoma (SMZL) is an indolent, low grade B-cell lymphoma primarily characterized 
by splenomegaly with variable involvement of lymph nodes, bone marrow, peripheral blood 
and other organs. It accounts for less than 1% of non-Hodgkin lymphoma2. The normal 
splenic marginal zone contains both memory B cells and naive B cells. In  parallel, unmutated 
as well as mutated immunoglobulin heavy chain genes are found3-5.
Gene expression profiling has revealed aberrant NF-B signaling in several lymphoma types 
such as diffuse large B-cell lymphoma (DLBCL)6, 7Hodgkin Lymphoma8 and SMZL9.  NF-
B is a transcription factor that regulates different cellular processes, such as cell growth and 
survival10 and is activated when normal B-cells respond to antigen.  In one subtype of  
DLBCL, of activated B-cell origin (ABC),  the constitutively activated NF-B signaling is 
due to mutations of important B-cell receptor (BCR) signaling genes11. These include 
mutations of the gene for caspase recruitment domain-containing protein 11 (CARD11)12 and 
2
mutations and/or deletions of an essential signaling subunit of BCR, CD7913. Of interest, Ngo 
et al.14 have described oncogenically active MYD88 mutations, an adaptor gene involved in 
Toll-like receptor signaling leading to NF-B activation in both ABC DLBCL (29 %) and in 
MALT lymphoma (9%), however SMZL were not studied. Interestingly, Rossi et al. 
demonstrated mutations and copy number alterations of genes such as TNFAIP3, IKBKB, 
BIRC3, TRAF3 and MAP3K14, involved in both the canonical and non-canonical NF-B
pathways in about 20% of SMZL15.  These authors found no mutations in CARD11 and 
MYD88. However, in a more recent study both CARD11 mutations (8.8 %) and MYD88 
mutations (13 %) have been detected in SMZL 16. The reason for the discrepancies between 
the two studies is unclear. The aim of this study was to analyze somatic mutations in 
additional genes, specifically CD79A and B, and study CARD11 and MYD88 gene mutations 
in our collection of SMZL cases. 
Methods
Tissue samples of 10 cases of SMZL and 13 control cases of other MZL  types, 7 nodal and 6 
extranodal MALT-type, were selected from the archives of the Department Pathology at The 
Norwegian Radium Hospital, Oslo University Hospital, Norway. All studied cases were 
reviewed to confirm diagnoses. The study was approved by the Regional Committee for 
Research Ethics. 
DNA was isolated from frozen tissue using the EZ1 tissue kit (Qiagen, Hilden, Germany). 
PCR was carried out using AmpliTaq Gold  polymerase (Applied Biosystem, Weiterstadt, 
Germany) according to the supplier’s instructions and using the following conditions: 94°C 
for 5 min followed by 34 cycles of denaturation 30s at 94°C, annealing 30s at 60°C (or 58°C) 
and extension 45 s at 72°C. PCR primers were used as described in table 1. The primer pair 
for CD79A (exon 4 and 5, NM_001783), CD79B (exon 5 and 6, NM_000626) and MYD88 
(part of exon 5, NM_002468) were designed using Primer-BLAST. The primer pairs used for 
CARD11 exon 5-10 (NM_032415) were as described in Lenz et al. (exon 5-10 is equal to 
exon 3-8 in their publication). The PCR products were verified on an Agilent 2100 
Bioanalyzer (Agilent Technologies) and an aliquot of the products was directly sequenced 
from both ends on a 3130 Genetic Analyzer (Applied Biosystems, Weiterstadt, Germany) 
using BigDye Terminator v1.1 (Applied Biosystems). A single nucleotide polymorphism, in 
one amino acid position (265) of the MYD88 gene was detected using PCR and SNaPshot 
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multiplex kit (Applied Biosystems) and analyzed with both forward and reverse primers by 
3130 Genetic Analyzer and GeneMapper 4.1 Software (Applied Biosystems).  
Results
A point mutation in the CD79B gene (Y196H) was detected in one SMZL case whereas a 
MYD88 gene (L265P) mutation was detected in another case. The CD79B mutation affected 
the first tyrosine of the CD79B immunoreceptor tyrosin-based activation motif (ITAM).  No 
mutations were detected in the CD79A gene or in the CARD11 gene in any of the SMZL 
cases (Table 1). Neither were mutations detected in all of the genes studied in the 13 control 
MZL samples.  
Of interest, the two SMZL cases with mutations of CD79B and MYD88, respectively, showed 
increased numbers of immunoblasts spread among the smaller and typical marginal zone 
lymphoma cells (Fig. 1). 
Discussion
In the present study we found a low frequency of mutations in four NF-B-signaling genes 
studied. Out of 10 cases of SMZL, only one mutation was found in CD79B and one mutation 
in MYD88 and none in CD79A and CARD11. This is in contrast to ABC  DLBCL  were 
CD79B mutations were detected in 21 %, MYD88 mutation (L265P) in 29 %  and CARD11 
mutations in 10 % of the cases 12-14. However, no CD79B mutations were detected in 16 
extranodal MZL cases (gastric MALT lymphoma) analyzed in the same study. The latter is in 
accordance with the data of our study. Davis et al 13 found a similar low frequency of  
MYD88 mutation (9 %) in gastric MALT lymphomas as we found in our SMZL cases.  
The mutation detected in CD79B affects a critical residue; the first tyrosine in the ITAM is 
replaced by another amino acid. Interestingly, this mutation is also found in almost all of the 
mutated ABC DLBCL cases. In ABC DLBCL this mutation increases the surface BCR 
expression, inhibits Lyn kinase activity and enhances activation of NF-B13. The MYD88 
L265P mutation detected in one of the SMZL cases occurs at a residue that is important for 
protein complex assembling and supports cell survival by activating NF-B and JAK-STAT 
signaling pathways 14. Although the somatic origin of the two mutations detected in our study 
could not be verified, these mutations have been shown by others to be functionally 
4
significant. It is therefore likely that mutations leading to amino acid substitutions 
demonstrated in two of the SMZL samples represent somatic mutations.  
A recent report has described mutations of multiple genes that cause deregulation of NF-B in 
DLBCL 11. Of these the NF-B negative regulator TNFAIP3 (A20) shows inactivation 
mutations and/or deletions in about 30 % of patients, thus contributing to NF-B activation. 
More importantly, A20 is also inactivated in 19 % if MZL, however with a frequency of only 
8 % in SMZL 16.  A low mutation frequency in the four NF-B-related genes studied is also 
reported by a recent study of  a large series of SMZL 17. Out of 101 cases of SMZL no 
mutations or copy number abnormalities of CARD11 and MYD88 were revealed, while 
CD79A and B were not studied. However, out of the other 20 genes studied, 5 of these genes 
showed mutations in 20 % of SMZL cases. Yan and colleagues 15 found a similar level of  
MYD88 mutation in (13 %) as in our study, however no mutations were detected in CD79A 
or CD79B in their series of 57 SMZL cases.
The cases with CD79B mutation and MYD88 mutation, respectively, showed increased 
numbers of immunoblast-like cells compared with the cases without mutation. This 
observation is of interest and might indicate that both mutations are associated with higher 
histological grade and therefore with risk of transformation. However, larger series with 
clinical follow-up data are needed to confirm the latter. 
In this study we found few activation mutations in four NF-B-signaling genes, including for 
the first time in CD79B. It is therefore likely that yet other genetic aberrations of signaling 
genes may contribute to the constitutive activation of NF-B in SMZL.
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Table 1:  Detected mutations in CD79A, CD79B, CARD11 and MYD88. 
Gene analyzed 
SMZL cases 
Detected mutations/ 
cases analyzed 
Other MZL cases 
Detected mutations/ 
cases analyzed 
CD79A
(exon 4 and 5) 
0/10 0/13
CD79B
(exon 5 and 6) 
1/10 0/13
CARD11
(exon 5-10) 
0/10 0/13
MYD88
(one hotspot) 
1/10 0/13
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Figure legend 
Figure 1. The left panel illustrates the lymphoma histology of a SMZL case without mutations 
in CD79A, CD79B, CARD11 or MYD88. The spleen shows homogenous infiltration with 
small cells with abundant clear cytoplasm (H&E, 400X). The right panel illustrates the 
lymphoma histology case with a CD79B mutation. The spleen shows infiltration with small 
lymphoid cells as well as with larger immunoblast-like cells (H&E, 400X). 
Figure 1 
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Supplementary Table 1. Primer pairs used for amplification and sequencing of CD79A, 
CD79B, CARD11 and MYD88 genes in SMZL. 
 FORWARD REVERSE 
CD79A exon 4 cat cca gga ggg tct gaa ag ccc taa cac aac tgc ccc ta 
CD79A exon 5 agg tgt cag ggt gct gat gt ccc act ggg gga ata tga ct 
CD79B exon 5 tct tgc aga atg cac ctc ac gca gcg tca cta tgt cct ca 
CD79B exon 6 tac gag gta agg aga ggg gc aga caa atg gca gct ctg gt 
CARD11 exon 5 gtc acc ctg gcg gag tag cc cag tgc ctc gtg ggc aga gt 
CARD11 exon 6 ctg gag aag gtt tct tgg agc aca ccc tgg cag gtt cat c 
CARD11 exon 7 ccc agg ccc tca tct ggt tg ccc agg ata cgc cca agc aa 
CARD11 exon 8 tcc cct atg tta cct ggt ctg tag tg gcc tgt gac ttc caa aaa agc c 
CARD11 exon 9 cct cag tgc cct cat ctg taa aat g caa agg aca agg agc cat tca ttg 
CARD11 exon 10 agc gag tcg cag gat ttc ca cca gaa gcc tgg gag gag ga 
MYD88 PCR tgc agg tgc cca tca gaa gcg cag aca gtg atg aac ctc agg atg c 
MYD88
SNaPshot
ccc ccc ccc c 
agg tgc cca tca gaa gcg ac cct tgt act tga tgg gga tc 
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Supplementary figure legends 
Supplementary Figure S1 
Electropherogram illustrating mutation Y196H of the CD79B gene in case of SMZL. 
Supplementary Figure S2 
Electropherogram of SNaPshot products illustrating the heterozygous loci detected in the 
MYD88 gene (L265P). The plot shows the relative fluorescence intensity versus the measured 
size in nucleotides of the products relative to the GeneScan-120 LIZ internal size standard 
(orange peaks). Bases are represented by the following colours: T = red, wild type; C = black, 
mutated; A = green, wild type G = blue, mutated.  
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Supplementary Figure S1.  
Supplementary FigureS2. 
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